HRP20210349T1 - Piridon amidi kao modulatori natrijevih kanala - Google Patents
Piridon amidi kao modulatori natrijevih kanala Download PDFInfo
- Publication number
- HRP20210349T1 HRP20210349T1 HRP20210349TT HRP20210349T HRP20210349T1 HR P20210349 T1 HRP20210349 T1 HR P20210349T1 HR P20210349T T HRP20210349T T HR P20210349TT HR P20210349 T HRP20210349 T HR P20210349T HR P20210349 T1 HRP20210349 T1 HR P20210349T1
- Authority
- HR
- Croatia
- Prior art keywords
- image
- oxo
- benzamide
- dihydropyridin
- trifluoromethyl
- Prior art date
Links
- -1 Pyridone amides Chemical class 0.000 title 1
- 108010052164 Sodium Channels Proteins 0.000 title 1
- 102000018674 Sodium Channels Human genes 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 53
- 150000001875 compounds Chemical class 0.000 claims 51
- 229910052736 halogen Inorganic materials 0.000 claims 45
- 150000002367 halogens Chemical class 0.000 claims 45
- 208000002193 Pain Diseases 0.000 claims 24
- 238000000034 method Methods 0.000 claims 15
- 208000004296 neuralgia Diseases 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 208000021722 neuropathic pain Diseases 0.000 claims 8
- YXHMFJXQQXHKRO-UHFFFAOYSA-N 2-(4-fluoro-2-methylphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound CC1=CC(F)=CC=C1OC1=CC(C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 YXHMFJXQQXHKRO-UHFFFAOYSA-N 0.000 claims 5
- CSKLRKQUNQCFCW-UHFFFAOYSA-N 4,5-dichloro-2-(4-fluoro-2-methoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound COC1=CC(F)=CC=C1OC1=CC(Cl)=C(Cl)C=C1C(=O)NC1=CC(=O)NC=C1 CSKLRKQUNQCFCW-UHFFFAOYSA-N 0.000 claims 5
- FZRXMWNNMIDCAX-UHFFFAOYSA-N 4-chloro-2-(4-fluoro-2-methylphenoxy)-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound CC1=CC(F)=CC=C1OC1=CC(Cl)=CC=C1C(=O)NC1=CC(=O)NC=C1 FZRXMWNNMIDCAX-UHFFFAOYSA-N 0.000 claims 5
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims 5
- 208000005298 acute pain Diseases 0.000 claims 5
- 229910052740 iodine Inorganic materials 0.000 claims 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 4
- 208000004550 Postoperative Pain Diseases 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 201000008482 osteoarthritis Diseases 0.000 claims 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- XNAAGHKLQDFJAV-UHFFFAOYSA-N 2-(4-fluoro-2-methoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-4-(1,1,2,2,2-pentafluoroethyl)benzamide Chemical compound COC1=CC(F)=CC=C1OC1=CC(C(F)(F)C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 XNAAGHKLQDFJAV-UHFFFAOYSA-N 0.000 claims 2
- SXHSUVHECGYYMY-UHFFFAOYSA-N 2-(4-fluoro-2-methylphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)benzamide Chemical compound CC1=CC(F)=CC=C1OC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 SXHSUVHECGYYMY-UHFFFAOYSA-N 0.000 claims 2
- URUKPZGNTWPRGW-UHFFFAOYSA-N 2-(4-fluorophenoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)benzamide Chemical compound C1=CC(F)=CC=C1OC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 URUKPZGNTWPRGW-UHFFFAOYSA-N 0.000 claims 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- 208000005890 Neuroma Diseases 0.000 claims 2
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 claims 2
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 2
- 239000000835 fiber Substances 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 201000005572 sensory peripheral neuropathy Diseases 0.000 claims 2
- 208000009935 visceral pain Diseases 0.000 claims 2
- IXFWXFPSQUGQID-UHFFFAOYSA-N 2-(2,3-difluoro-4-methylphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)benzamide Chemical compound FC1=C(F)C(C)=CC=C1OC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 IXFWXFPSQUGQID-UHFFFAOYSA-N 0.000 claims 1
- FPKSPIQOEJACSE-UHFFFAOYSA-N 2-(2,4-difluorophenoxy)-n-(2-oxo-1h-pyridin-4-yl)-4,6-bis(trifluoromethyl)benzamide Chemical compound FC1=CC(F)=CC=C1OC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1C(=O)NC1=CC(=O)NC=C1 FPKSPIQOEJACSE-UHFFFAOYSA-N 0.000 claims 1
- JLOCNBNTRGBNSU-UHFFFAOYSA-N 2-(2,4-difluorophenoxy)-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound FC1=CC(F)=CC=C1OC1=CC(C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 JLOCNBNTRGBNSU-UHFFFAOYSA-N 0.000 claims 1
- UMDJUPAXVBHNKS-UHFFFAOYSA-N 2-(2,4-difluorophenoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethoxy)benzamide Chemical compound FC1=CC(F)=CC=C1OC1=CC=C(OC(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 UMDJUPAXVBHNKS-UHFFFAOYSA-N 0.000 claims 1
- UFVVLUUDTNDRGT-UHFFFAOYSA-N 2-(2,4-difluorophenoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)benzamide Chemical compound FC1=CC(F)=CC=C1OC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 UFVVLUUDTNDRGT-UHFFFAOYSA-N 0.000 claims 1
- IZWSTOWJMYCSFT-UHFFFAOYSA-N 2-(2,6-difluorophenoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethoxy)benzamide Chemical compound FC1=CC=CC(F)=C1OC1=CC=C(OC(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 IZWSTOWJMYCSFT-UHFFFAOYSA-N 0.000 claims 1
- KREVBSDXGCKOJM-UHFFFAOYSA-N 2-(2,6-difluorophenoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)benzamide Chemical compound FC1=CC=CC(F)=C1OC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 KREVBSDXGCKOJM-UHFFFAOYSA-N 0.000 claims 1
- SUDPZTYFJSTPQI-UHFFFAOYSA-N 2-(2-chloro-3-fluoro-4-methoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound ClC1=C(F)C(OC)=CC=C1OC1=CC(C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 SUDPZTYFJSTPQI-UHFFFAOYSA-N 0.000 claims 1
- XENPFDQDTNUZPA-UHFFFAOYSA-N 2-(2-chloro-4-fluorophenoxy)-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound ClC1=CC(F)=CC=C1OC1=CC(C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 XENPFDQDTNUZPA-UHFFFAOYSA-N 0.000 claims 1
- IJLRJKVKJNUIJD-UHFFFAOYSA-N 2-(2-chloro-4-fluorophenoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethoxy)benzamide Chemical compound ClC1=CC(F)=CC=C1OC1=CC=C(OC(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 IJLRJKVKJNUIJD-UHFFFAOYSA-N 0.000 claims 1
- BVWMEUDWRCWKGL-UHFFFAOYSA-N 2-(2-chloro-4-fluorophenoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)benzamide Chemical compound ClC1=CC(F)=CC=C1OC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 BVWMEUDWRCWKGL-UHFFFAOYSA-N 0.000 claims 1
- CGHVTPLFSBFCMC-UHFFFAOYSA-N 2-(2-chloro-4-methoxyphenoxy)-5-fluoro-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound ClC1=CC(OC)=CC=C1OC1=CC=C(F)C=C1C(=O)NC1=CC(=O)NC=C1 CGHVTPLFSBFCMC-UHFFFAOYSA-N 0.000 claims 1
- JNNYSEIQBAVVNL-UHFFFAOYSA-N 2-(2-chloro-4-methoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)benzamide Chemical compound ClC1=CC(OC)=CC=C1OC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 JNNYSEIQBAVVNL-UHFFFAOYSA-N 0.000 claims 1
- CBWXHMITTMOYOY-UHFFFAOYSA-N 2-(2-chlorophenoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)benzamide Chemical compound C1=CNC(=O)C=C1NC(=O)C1=CC(C(F)(F)F)=CC=C1OC1=CC=CC=C1Cl CBWXHMITTMOYOY-UHFFFAOYSA-N 0.000 claims 1
- XMZFDPKNGIFRLZ-UHFFFAOYSA-N 2-(2-ethoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)benzamide Chemical compound CCOC1=CC=CC=C1OC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 XMZFDPKNGIFRLZ-UHFFFAOYSA-N 0.000 claims 1
- GGKJOYYMGVWXAT-UHFFFAOYSA-N 2-(2-fluoro-4-methoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound FC1=CC(OC)=CC=C1OC1=CC(C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 GGKJOYYMGVWXAT-UHFFFAOYSA-N 0.000 claims 1
- ICZIAJCVIIUREC-UHFFFAOYSA-N 2-(2-fluoro-4-methoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)benzamide Chemical compound FC1=CC(OC)=CC=C1OC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 ICZIAJCVIIUREC-UHFFFAOYSA-N 0.000 claims 1
- OMKAJNDPKOXDJE-UHFFFAOYSA-N 2-(2-fluoro-6-methoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)benzamide Chemical compound COC1=CC=CC(F)=C1OC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 OMKAJNDPKOXDJE-UHFFFAOYSA-N 0.000 claims 1
- YDRSKXBOYKSOJN-UHFFFAOYSA-N 2-(2-fluoro-6-methylphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethoxy)benzamide Chemical compound CC1=CC=CC(F)=C1OC1=CC=C(OC(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 YDRSKXBOYKSOJN-UHFFFAOYSA-N 0.000 claims 1
- KUCYRCUGXDBLAO-UHFFFAOYSA-N 2-(2-methoxy-4-methylphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)benzamide Chemical compound COC1=CC(C)=CC=C1OC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 KUCYRCUGXDBLAO-UHFFFAOYSA-N 0.000 claims 1
- FAHBRZBMNSAQQB-UHFFFAOYSA-N 2-(2-methylphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound CC1=CC=CC=C1OC1=CC(C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 FAHBRZBMNSAQQB-UHFFFAOYSA-N 0.000 claims 1
- MASHRDPYQKFCAR-UHFFFAOYSA-N 2-(2-methylphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethoxy)benzamide Chemical compound CC1=CC=CC=C1OC1=CC=C(OC(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 MASHRDPYQKFCAR-UHFFFAOYSA-N 0.000 claims 1
- PIQAUSNVLROXMR-UHFFFAOYSA-N 2-(2-methylphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)benzamide Chemical compound CC1=CC=CC=C1OC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 PIQAUSNVLROXMR-UHFFFAOYSA-N 0.000 claims 1
- JUDYBFMPBKSTBB-UHFFFAOYSA-N 2-(2-methylpropoxy)-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound CC(C)COC1=CC(C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 JUDYBFMPBKSTBB-UHFFFAOYSA-N 0.000 claims 1
- AWWWPDPNSMZXCC-UHFFFAOYSA-N 2-(2-methylpropoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)benzamide Chemical compound CC(C)COC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 AWWWPDPNSMZXCC-UHFFFAOYSA-N 0.000 claims 1
- FNYNPPMOZIJFAC-UHFFFAOYSA-N 2-(2-methylpyridin-3-yl)oxy-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound CC1=NC=CC=C1OC1=CC(C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 FNYNPPMOZIJFAC-UHFFFAOYSA-N 0.000 claims 1
- QULMOQQNFDJHJA-UHFFFAOYSA-N 2-(2-methylpyridin-3-yl)oxy-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethoxy)benzamide Chemical compound CC1=NC=CC=C1OC1=CC=C(OC(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 QULMOQQNFDJHJA-UHFFFAOYSA-N 0.000 claims 1
- XLUICCIIQQVLBW-UHFFFAOYSA-N 2-(2-methylpyridin-3-yl)oxy-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)benzamide Chemical compound CC1=NC=CC=C1OC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 XLUICCIIQQVLBW-UHFFFAOYSA-N 0.000 claims 1
- REFSPUPAKCCVAD-UHFFFAOYSA-N 2-(3-bicyclo[2.2.1]heptanyloxy)-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound C1C(C2)CCC2C1OC1=CC(C(F)(F)F)=CC=C1C(=O)NC=1C=CNC(=O)C=1 REFSPUPAKCCVAD-UHFFFAOYSA-N 0.000 claims 1
- XLENMSSHHOXWHN-UHFFFAOYSA-N 2-(3-fluoro-2-methoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound COC1=C(F)C=CC=C1OC1=CC(C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 XLENMSSHHOXWHN-UHFFFAOYSA-N 0.000 claims 1
- XFYJZSKHXSPHJR-UHFFFAOYSA-N 2-(3-fluoro-2-methoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)benzamide Chemical compound COC1=C(F)C=CC=C1OC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 XFYJZSKHXSPHJR-UHFFFAOYSA-N 0.000 claims 1
- ZUFQSMFAKHTNSW-UHFFFAOYSA-N 2-(3-fluoro-4-methoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-4-(1,1,2,2,2-pentafluoroethyl)benzamide Chemical compound C1=C(F)C(OC)=CC=C1OC1=CC(C(F)(F)C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 ZUFQSMFAKHTNSW-UHFFFAOYSA-N 0.000 claims 1
- GIJKDQHCVRCMIN-UHFFFAOYSA-N 2-(3-fluoro-4-methoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound C1=C(F)C(OC)=CC=C1OC1=CC(C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 GIJKDQHCVRCMIN-UHFFFAOYSA-N 0.000 claims 1
- OFZBNADUYSHVNR-UHFFFAOYSA-N 2-(3-fluoro-4-methoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)benzamide Chemical compound C1=C(F)C(OC)=CC=C1OC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 OFZBNADUYSHVNR-UHFFFAOYSA-N 0.000 claims 1
- GYDKJXLRYAYBAQ-UHFFFAOYSA-N 2-(3-fluoro-5-methoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)benzamide Chemical compound COC1=CC(F)=CC(OC=2C(=CC(=CC=2)C(F)(F)F)C(=O)NC2=CC(=O)NC=C2)=C1 GYDKJXLRYAYBAQ-UHFFFAOYSA-N 0.000 claims 1
- KICOFBPOACPQPG-UHFFFAOYSA-N 2-(3-methylbutoxy)-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound CC(C)CCOC1=CC(C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 KICOFBPOACPQPG-UHFFFAOYSA-N 0.000 claims 1
- FWASJBQVSBHBNK-UHFFFAOYSA-N 2-(4-chloro-2-fluorophenoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)benzamide Chemical compound FC1=CC(Cl)=CC=C1OC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 FWASJBQVSBHBNK-UHFFFAOYSA-N 0.000 claims 1
- WSAJJTWYTKFRMU-UHFFFAOYSA-N 2-(4-chloro-2-methylphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)benzamide Chemical compound CC1=CC(Cl)=CC=C1OC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 WSAJJTWYTKFRMU-UHFFFAOYSA-N 0.000 claims 1
- IVXWSJDIJWTMBP-UHFFFAOYSA-N 2-(4-chlorophenoxy)-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound C=1C=C(Cl)C=CC=1OC1=CC(C(F)(F)F)=CC=C1C(=O)NC=1C=CNC(=O)C=1 IVXWSJDIJWTMBP-UHFFFAOYSA-N 0.000 claims 1
- AKDINRARGVIZNO-UHFFFAOYSA-N 2-(4-chlorophenoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)benzamide Chemical compound C1=CNC(=O)C=C1NC(=O)C1=CC(C(F)(F)F)=CC=C1OC1=CC=C(Cl)C=C1 AKDINRARGVIZNO-UHFFFAOYSA-N 0.000 claims 1
- NCISSLADDFSKLN-UHFFFAOYSA-N 2-(4-cyanophenoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)benzamide Chemical compound C1=CNC(=O)C=C1NC(=O)C1=CC(C(F)(F)F)=CC=C1OC1=CC=C(C#N)C=C1 NCISSLADDFSKLN-UHFFFAOYSA-N 0.000 claims 1
- HPURRFIKNKVIFS-UHFFFAOYSA-N 2-(4-cyclopropylphenoxy)-5-fluoro-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound C1=CNC(=O)C=C1NC(=O)C1=CC(F)=CC=C1OC(C=C1)=CC=C1C1CC1 HPURRFIKNKVIFS-UHFFFAOYSA-N 0.000 claims 1
- LNRALXGEGPHUEQ-UHFFFAOYSA-N 2-(4-ethoxyphenoxy)-5-fluoro-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound C1=CC(OCC)=CC=C1OC1=CC=C(F)C=C1C(=O)NC1=CC(=O)NC=C1 LNRALXGEGPHUEQ-UHFFFAOYSA-N 0.000 claims 1
- OJJVDLJKYRQHKJ-UHFFFAOYSA-N 2-(4-ethoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)benzamide Chemical compound C1=CC(OCC)=CC=C1OC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 OJJVDLJKYRQHKJ-UHFFFAOYSA-N 0.000 claims 1
- OFJWZNKJBMVLPX-UHFFFAOYSA-N 2-(4-fluoro-2-methoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-4,6-bis(trifluoromethyl)benzamide Chemical compound COC1=CC(F)=CC=C1OC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1C(=O)NC1=CC(=O)NC=C1 OFJWZNKJBMVLPX-UHFFFAOYSA-N 0.000 claims 1
- OZJSEVZVZWZBIT-UHFFFAOYSA-N 2-(4-fluoro-2-methoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound COC1=CC(F)=CC=C1OC1=CC(C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 OZJSEVZVZWZBIT-UHFFFAOYSA-N 0.000 claims 1
- GFDFBVYVIAOKEU-UHFFFAOYSA-N 2-(4-fluoro-2-methoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethoxy)benzamide Chemical compound COC1=CC(F)=CC=C1OC1=CC=C(OC(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 GFDFBVYVIAOKEU-UHFFFAOYSA-N 0.000 claims 1
- JKAMBBDGLZFTHQ-UHFFFAOYSA-N 2-(4-fluoro-2-methoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)benzamide Chemical compound COC1=CC(F)=CC=C1OC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 JKAMBBDGLZFTHQ-UHFFFAOYSA-N 0.000 claims 1
- OJGBGGHWKBSYTM-UHFFFAOYSA-N 2-(4-fluoro-2-methylphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-4,6-bis(trifluoromethyl)benzamide Chemical compound CC1=CC(F)=CC=C1OC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1C(=O)NC1=CC(=O)NC=C1 OJGBGGHWKBSYTM-UHFFFAOYSA-N 0.000 claims 1
- OGNHUCWKIBGDPU-UHFFFAOYSA-N 2-(4-fluoro-2-methylphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-4-(1,1,2,2,2-pentafluoroethyl)benzamide Chemical compound CC1=CC(F)=CC=C1OC1=CC(C(F)(F)C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 OGNHUCWKIBGDPU-UHFFFAOYSA-N 0.000 claims 1
- UXNUHKSSUVUOKZ-UHFFFAOYSA-N 2-(4-fluoro-2-methylphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethoxy)benzamide Chemical compound CC1=CC(F)=CC=C1OC1=CC=C(OC(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 UXNUHKSSUVUOKZ-UHFFFAOYSA-N 0.000 claims 1
- QYLLDXJQSXDYLQ-UHFFFAOYSA-N 2-(4-fluorophenoxy)-n-(2-oxo-1h-pyridin-4-yl)-4,6-bis(trifluoromethyl)benzamide Chemical compound C1=CC(F)=CC=C1OC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1C(=O)NC1=CC(=O)NC=C1 QYLLDXJQSXDYLQ-UHFFFAOYSA-N 0.000 claims 1
- AJZDQSWVXBSGJM-UHFFFAOYSA-N 2-(4-fluorophenoxy)-n-(2-oxo-1h-pyridin-4-yl)-4-(1,1,2,2,2-pentafluoroethyl)benzamide Chemical compound C1=CC(F)=CC=C1OC1=CC(C(F)(F)C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 AJZDQSWVXBSGJM-UHFFFAOYSA-N 0.000 claims 1
- DMQWJYJEJRIDBI-UHFFFAOYSA-N 2-(4-fluorophenoxy)-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound C1=CC(F)=CC=C1OC1=CC(C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 DMQWJYJEJRIDBI-UHFFFAOYSA-N 0.000 claims 1
- XQOGUSYHWGLZNJ-UHFFFAOYSA-N 2-(4-fluorophenoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethoxy)benzamide Chemical compound C1=CC(F)=CC=C1OC1=CC=C(OC(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 XQOGUSYHWGLZNJ-UHFFFAOYSA-N 0.000 claims 1
- FJCCQQXMASEMDV-UHFFFAOYSA-N 2-(4-fluorophenoxy)-n-(2-oxo-1h-pyridin-4-yl)-6-(trifluoromethyl)benzamide Chemical compound C1=CC(F)=CC=C1OC1=CC=CC(C(F)(F)F)=C1C(=O)NC1=CC(=O)NC=C1 FJCCQQXMASEMDV-UHFFFAOYSA-N 0.000 claims 1
- XOCXALHCXDJWIV-UHFFFAOYSA-N 2-(4-fluorophenoxy)-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound C1=CC(F)=CC=C1OC1=CC=CC=C1C(=O)NC1=CC(=O)NC=C1 XOCXALHCXDJWIV-UHFFFAOYSA-N 0.000 claims 1
- XEDSOXUCOFSPMG-UHFFFAOYSA-N 2-(4-fluorophenoxy)-n-(6-oxo-1h-pyridin-3-yl)-4-(trifluoromethyl)benzamide Chemical compound C1=CC(F)=CC=C1OC1=CC(C(F)(F)F)=CC=C1C(=O)NC1=CNC(=O)C=C1 XEDSOXUCOFSPMG-UHFFFAOYSA-N 0.000 claims 1
- XUGUKAXHZIOGLG-UHFFFAOYSA-N 2-(4-fluorophenoxy)-n-(6-oxo-1h-pyridin-3-yl)-5-(trifluoromethyl)benzamide Chemical compound C1=CC(F)=CC=C1OC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CNC(=O)C=C1 XUGUKAXHZIOGLG-UHFFFAOYSA-N 0.000 claims 1
- ZZVCSGUMUITZAJ-UHFFFAOYSA-N 2-(4-fluorophenoxy)-n-(6-oxo-1h-pyridin-3-yl)benzamide Chemical compound C1=CC(F)=CC=C1OC1=CC=CC=C1C(=O)NC1=CNC(=O)C=C1 ZZVCSGUMUITZAJ-UHFFFAOYSA-N 0.000 claims 1
- DJONINYBNANXIN-UHFFFAOYSA-N 2-(4-fluorophenoxy)-n-[1-(2-hydroxyethyl)-2-oxopyridin-4-yl]-4-(trifluoromethyl)benzamide Chemical compound O=C1N(CCO)C=CC(NC(=O)C=2C(=CC(=CC=2)C(F)(F)F)OC=2C=CC(F)=CC=2)=C1 DJONINYBNANXIN-UHFFFAOYSA-N 0.000 claims 1
- GOHNZFHVWZRGGX-UHFFFAOYSA-N 2-(4-methoxy-2-methylphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)benzamide Chemical compound CC1=CC(OC)=CC=C1OC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 GOHNZFHVWZRGGX-UHFFFAOYSA-N 0.000 claims 1
- IHXQTRXZYHPGIQ-UHFFFAOYSA-N 2-(4-methoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)benzamide Chemical compound C1=CC(OC)=CC=C1OC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 IHXQTRXZYHPGIQ-UHFFFAOYSA-N 0.000 claims 1
- PRDWHZNGVONJAX-UHFFFAOYSA-N 2-(4-methylphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound C1=CC(C)=CC=C1OC1=CC(C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 PRDWHZNGVONJAX-UHFFFAOYSA-N 0.000 claims 1
- IQNGIYJIIGTIOM-UHFFFAOYSA-N 2-(4-methylphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethoxy)benzamide Chemical compound C1=CC(C)=CC=C1OC1=CC=C(OC(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 IQNGIYJIIGTIOM-UHFFFAOYSA-N 0.000 claims 1
- JYSHLENEZRKPDK-UHFFFAOYSA-N 2-(4-methylphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)benzamide Chemical compound C1=CC(C)=CC=C1OC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 JYSHLENEZRKPDK-UHFFFAOYSA-N 0.000 claims 1
- ROWKGBJMLVUFFH-UHFFFAOYSA-N 2-(5-fluoro-2-methoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)benzamide Chemical compound COC1=CC=C(F)C=C1OC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 ROWKGBJMLVUFFH-UHFFFAOYSA-N 0.000 claims 1
- CUVWAXHFLWGMGR-UHFFFAOYSA-N 2-(5-fluoro-2-methylphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)benzamide Chemical compound CC1=CC=C(F)C=C1OC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 CUVWAXHFLWGMGR-UHFFFAOYSA-N 0.000 claims 1
- GVUYQPUAVUSQLF-UHFFFAOYSA-N 2-(6-methylpyridin-3-yl)oxy-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound C1=NC(C)=CC=C1OC1=CC(C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 GVUYQPUAVUSQLF-UHFFFAOYSA-N 0.000 claims 1
- IKWWVCWYCSDROX-UHFFFAOYSA-N 2-(cyclopentylmethoxy)-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound C1CCCC1COC1=CC(C(F)(F)F)=CC=C1C(=O)NC=1C=CNC(=O)C=1 IKWWVCWYCSDROX-UHFFFAOYSA-N 0.000 claims 1
- CUVYLUQYLWTAQS-UHFFFAOYSA-N 2-(cyclopentylmethoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethoxy)benzamide Chemical compound C1=CNC(=O)C=C1NC(=O)C1=CC(OC(F)(F)F)=CC=C1OCC1CCCC1 CUVYLUQYLWTAQS-UHFFFAOYSA-N 0.000 claims 1
- NUTCBCQHXFPEBM-UHFFFAOYSA-N 2-(cyclopentylmethoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)benzamide Chemical compound C1=CNC(=O)C=C1NC(=O)C1=CC(C(F)(F)F)=CC=C1OCC1CCCC1 NUTCBCQHXFPEBM-UHFFFAOYSA-N 0.000 claims 1
- DTEOYBYVOKRPOM-UHFFFAOYSA-N 2-(oxolan-3-ylmethoxy)-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound C1COCC1COC1=CC(C(F)(F)F)=CC=C1C(=O)NC=1C=CNC(=O)C=1 DTEOYBYVOKRPOM-UHFFFAOYSA-N 0.000 claims 1
- KIVKLMKQCASUFG-UHFFFAOYSA-N 2-[(1-methylcyclopropyl)methoxy]-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound C=1C(C(F)(F)F)=CC=C(C(=O)NC2=CC(=O)NC=C2)C=1OCC1(C)CC1 KIVKLMKQCASUFG-UHFFFAOYSA-N 0.000 claims 1
- JBUFOAWTJMVZKG-UHFFFAOYSA-N 2-[(2,2-difluorocyclopropyl)methoxy]-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound C1C(F)(F)C1COC1=CC(C(F)(F)F)=CC=C1C(=O)NC=1C=CNC(=O)C=1 JBUFOAWTJMVZKG-UHFFFAOYSA-N 0.000 claims 1
- FCWGDENQRAUXMY-UHFFFAOYSA-N 2-[(2,2-dimethylcyclopropyl)methoxy]-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound CC1(C)CC1COC1=CC(C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 FCWGDENQRAUXMY-UHFFFAOYSA-N 0.000 claims 1
- UATNPCZOIUWDAA-UHFFFAOYSA-N 2-[(2,2-dimethylcyclopropyl)methoxy]-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethoxy)benzamide Chemical compound CC1(C)CC1COC1=CC=C(OC(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 UATNPCZOIUWDAA-UHFFFAOYSA-N 0.000 claims 1
- ICXCKCQKMZSVBF-UHFFFAOYSA-N 2-[(2,2-dimethylcyclopropyl)methoxy]-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)benzamide Chemical compound CC1(C)CC1COC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 ICXCKCQKMZSVBF-UHFFFAOYSA-N 0.000 claims 1
- WGJBFMMLUYGFBM-UHFFFAOYSA-N 2-[(5-fluoro-2-hydroxyphenyl)methoxy]-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound OC1=CC=C(F)C=C1COC1=CC(C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 WGJBFMMLUYGFBM-UHFFFAOYSA-N 0.000 claims 1
- IWRIRVFYRTUDIJ-UHFFFAOYSA-N 2-[2-(difluoromethoxy)phenoxy]-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound FC(F)OC1=CC=CC=C1OC1=CC(C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 IWRIRVFYRTUDIJ-UHFFFAOYSA-N 0.000 claims 1
- WGGALQWPTKGQLX-UHFFFAOYSA-N 2-[2-(difluoromethoxy)phenoxy]-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)benzamide Chemical compound FC(F)OC1=CC=CC=C1OC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 WGGALQWPTKGQLX-UHFFFAOYSA-N 0.000 claims 1
- CRIVLAVCQBIGSC-UHFFFAOYSA-N 2-[4-(2-methoxyethoxy)phenoxy]-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound C1=CC(OCCOC)=CC=C1OC1=CC(C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 CRIVLAVCQBIGSC-UHFFFAOYSA-N 0.000 claims 1
- XBCPDKDJZGECMM-UHFFFAOYSA-N 2-[4-(cyclopropylmethoxy)phenoxy]-5-fluoro-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound C1=CNC(=O)C=C1NC(=O)C1=CC(F)=CC=C1OC(C=C1)=CC=C1OCC1CC1 XBCPDKDJZGECMM-UHFFFAOYSA-N 0.000 claims 1
- YWQDQDUGUYEIPV-UHFFFAOYSA-N 2-[4-(difluoromethoxy)phenoxy]-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound C1=CC(OC(F)F)=CC=C1OC1=CC(C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 YWQDQDUGUYEIPV-UHFFFAOYSA-N 0.000 claims 1
- KWARURQEBURTJY-UHFFFAOYSA-N 2-[4-(difluoromethoxy)phenoxy]-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)benzamide Chemical compound C1=CC(OC(F)F)=CC=C1OC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 KWARURQEBURTJY-UHFFFAOYSA-N 0.000 claims 1
- HAHBFCDZJMZPDT-UHFFFAOYSA-N 2-[4-fluoro-2-(hydroxymethyl)phenoxy]-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound OCC1=CC(F)=CC=C1OC1=CC(C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 HAHBFCDZJMZPDT-UHFFFAOYSA-N 0.000 claims 1
- XNISXOXNXGRBGI-BVUQATHDSA-N 2-[[(1r,5s)-3-bicyclo[3.1.0]hexanyl]oxy]-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)benzamide Chemical compound C=1C(C(F)(F)F)=CC=C(OC2C[C@H]3C[C@H]3C2)C=1C(=O)NC=1C=CNC(=O)C=1 XNISXOXNXGRBGI-BVUQATHDSA-N 0.000 claims 1
- UGWDFRBDGPKGJG-BVUQATHDSA-N 2-[[(1s,5r)-3-bicyclo[3.1.0]hexanyl]oxy]-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound C([C@H]1C[C@H]1C1)C1OC1=CC(C(F)(F)F)=CC=C1C(=O)NC=1C=CNC(=O)C=1 UGWDFRBDGPKGJG-BVUQATHDSA-N 0.000 claims 1
- REFSPUPAKCCVAD-ZEPSKSRBSA-N 2-[[(3r)-3-bicyclo[2.2.1]heptanyl]oxy]-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound O([C@H]1C2CCC(C2)C1)C1=CC(C(F)(F)F)=CC=C1C(=O)NC=1C=CNC(=O)C=1 REFSPUPAKCCVAD-ZEPSKSRBSA-N 0.000 claims 1
- WRONUICUDKTKHA-UHFFFAOYSA-N 2-cyclobutyloxy-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound C1CCC1OC1=CC(C(F)(F)F)=CC=C1C(=O)NC=1C=CNC(=O)C=1 WRONUICUDKTKHA-UHFFFAOYSA-N 0.000 claims 1
- DITZNZYXKSFLJE-UHFFFAOYSA-N 2-cyclohexyloxy-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound C1CCCCC1OC1=CC(C(F)(F)F)=CC=C1C(=O)NC=1C=CNC(=O)C=1 DITZNZYXKSFLJE-UHFFFAOYSA-N 0.000 claims 1
- KXHVTNRVAJHNTH-UHFFFAOYSA-N 2-cyclohexyloxy-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethoxy)benzamide Chemical compound C1=CNC(=O)C=C1NC(=O)C1=CC(OC(F)(F)F)=CC=C1OC1CCCCC1 KXHVTNRVAJHNTH-UHFFFAOYSA-N 0.000 claims 1
- DSGSRMJPDQBTMM-UHFFFAOYSA-N 4,5-dichloro-2-(3-fluoro-4-methoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound C1=C(F)C(OC)=CC=C1OC1=CC(Cl)=C(Cl)C=C1C(=O)NC1=CC(=O)NC=C1 DSGSRMJPDQBTMM-UHFFFAOYSA-N 0.000 claims 1
- MEEMNCAUXAWBBT-UHFFFAOYSA-N 4,5-dichloro-2-(4-fluorophenoxy)-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound C1=CC(F)=CC=C1OC1=CC(Cl)=C(Cl)C=C1C(=O)NC1=CC(=O)NC=C1 MEEMNCAUXAWBBT-UHFFFAOYSA-N 0.000 claims 1
- UTKZKXRKSFATLD-UHFFFAOYSA-N 4-chloro-2-(2,4-difluorophenoxy)-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound FC1=CC(F)=CC=C1OC1=CC(Cl)=CC=C1C(=O)NC1=CC(=O)NC=C1 UTKZKXRKSFATLD-UHFFFAOYSA-N 0.000 claims 1
- VZVFDJLFHJSULP-UHFFFAOYSA-N 4-chloro-2-(2,6-difluorophenoxy)-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound FC1=CC=CC(F)=C1OC1=CC(Cl)=CC=C1C(=O)NC1=CC(=O)NC=C1 VZVFDJLFHJSULP-UHFFFAOYSA-N 0.000 claims 1
- WLRVZQGFKCYIOQ-UHFFFAOYSA-N 4-chloro-2-(2-chloro-4-fluorophenoxy)-5-fluoro-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound ClC1=CC(F)=CC=C1OC1=CC(Cl)=C(F)C=C1C(=O)NC1=CC(=O)NC=C1 WLRVZQGFKCYIOQ-UHFFFAOYSA-N 0.000 claims 1
- GOXQSPDBNHQSLA-UHFFFAOYSA-N 4-chloro-2-(2-chloro-4-fluorophenoxy)-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound ClC1=CC(F)=CC=C1OC1=CC(Cl)=CC=C1C(=O)NC1=CC(=O)NC=C1 GOXQSPDBNHQSLA-UHFFFAOYSA-N 0.000 claims 1
- ZSNOWMCACAKMOG-UHFFFAOYSA-N 4-chloro-2-(2-chloro-6-fluorophenoxy)-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound FC1=CC=CC(Cl)=C1OC1=CC(Cl)=CC=C1C(=O)NC1=CC(=O)NC=C1 ZSNOWMCACAKMOG-UHFFFAOYSA-N 0.000 claims 1
- KGNADFFDVVNWDF-UHFFFAOYSA-N 4-chloro-2-(2-fluoro-6-methylphenoxy)-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound CC1=CC=CC(F)=C1OC1=CC(Cl)=CC=C1C(=O)NC1=CC(=O)NC=C1 KGNADFFDVVNWDF-UHFFFAOYSA-N 0.000 claims 1
- UUAIQHMLXPMLDV-UHFFFAOYSA-N 4-chloro-2-(4-fluoro-2-methoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound COC1=CC(F)=CC=C1OC1=CC(Cl)=CC=C1C(=O)NC1=CC(=O)NC=C1 UUAIQHMLXPMLDV-UHFFFAOYSA-N 0.000 claims 1
- NDMNISGHBWDHTB-UHFFFAOYSA-N 4-chloro-2-(4-fluorophenoxy)-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound C1=CC(F)=CC=C1OC1=CC(Cl)=CC=C1C(=O)NC1=CC(=O)NC=C1 NDMNISGHBWDHTB-UHFFFAOYSA-N 0.000 claims 1
- LVBOJKUDPCHPOK-UHFFFAOYSA-N 4-chloro-n-(2-oxo-1h-pyridin-4-yl)-2-(4,4,4-trifluorobutoxy)benzamide Chemical compound FC(F)(F)CCCOC1=CC(Cl)=CC=C1C(=O)NC1=CC(=O)NC=C1 LVBOJKUDPCHPOK-UHFFFAOYSA-N 0.000 claims 1
- NECWBBPMTPYKFR-UHFFFAOYSA-N 4-chloro-n-(2-oxo-1h-pyridin-4-yl)-2-[6-(trifluoromethyl)pyridin-3-yl]oxybenzamide Chemical compound C1=NC(C(F)(F)F)=CC=C1OC1=CC(Cl)=CC=C1C(=O)NC1=CC(=O)NC=C1 NECWBBPMTPYKFR-UHFFFAOYSA-N 0.000 claims 1
- IBHSESFTJVMJEA-UHFFFAOYSA-N 4-cyano-2-(4-fluoro-2-methoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound COC1=CC(F)=CC=C1OC1=CC(C#N)=CC=C1C(=O)NC1=CC(=O)NC=C1 IBHSESFTJVMJEA-UHFFFAOYSA-N 0.000 claims 1
- FYMIWSLUIKOSOZ-UHFFFAOYSA-N 4-cyano-2-(4-fluoro-2-methylphenoxy)-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound CC1=CC(F)=CC=C1OC1=CC(C#N)=CC=C1C(=O)NC1=CC(=O)NC=C1 FYMIWSLUIKOSOZ-UHFFFAOYSA-N 0.000 claims 1
- AWWVNDFZXGVFPE-UHFFFAOYSA-N 4-cyano-2-(4-fluorophenoxy)-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound C1=CC(F)=CC=C1OC1=CC(C#N)=CC=C1C(=O)NC1=CC(=O)NC=C1 AWWVNDFZXGVFPE-UHFFFAOYSA-N 0.000 claims 1
- QUPOUNZWMBLXGJ-UHFFFAOYSA-N 4-tert-butyl-n-(1-methyl-2-oxopyridin-4-yl)-2-[6-(trifluoromethyl)pyridin-3-yl]oxybenzamide Chemical compound O=C1N(C)C=CC(NC(=O)C=2C(=CC(=CC=2)C(C)(C)C)OC=2C=NC(=CC=2)C(F)(F)F)=C1 QUPOUNZWMBLXGJ-UHFFFAOYSA-N 0.000 claims 1
- LQEGEICTHYLCCB-UHFFFAOYSA-N 4-tert-butyl-n-(1-methyl-6-oxopyridin-3-yl)-2-[6-(trifluoromethyl)pyridin-3-yl]oxybenzamide Chemical compound C1=CC(=O)N(C)C=C1NC(=O)C1=CC=C(C(C)(C)C)C=C1OC1=CC=C(C(F)(F)F)N=C1 LQEGEICTHYLCCB-UHFFFAOYSA-N 0.000 claims 1
- CKTPSKKTZVSXLI-UHFFFAOYSA-N 4-tert-butyl-n-(2-oxo-1h-pyridin-4-yl)-2-[6-(trifluoromethyl)pyridin-3-yl]oxybenzamide Chemical compound C=1C=C(C(F)(F)F)N=CC=1OC1=CC(C(C)(C)C)=CC=C1C(=O)NC=1C=CNC(=O)C=1 CKTPSKKTZVSXLI-UHFFFAOYSA-N 0.000 claims 1
- PNSVJQJVGCLXPD-UHFFFAOYSA-N 4-tert-butyl-n-(6-oxo-1h-pyridin-3-yl)-2-[6-(trifluoromethyl)pyridin-3-yl]oxybenzamide Chemical compound C=1C=C(C(F)(F)F)N=CC=1OC1=CC(C(C)(C)C)=CC=C1C(=O)NC=1C=CC(=O)NC=1 PNSVJQJVGCLXPD-UHFFFAOYSA-N 0.000 claims 1
- MFOFLSYIDKCECT-UHFFFAOYSA-N 5-chloro-2-(2,4-difluorophenoxy)-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound FC1=CC(F)=CC=C1OC1=CC=C(Cl)C=C1C(=O)NC1=CC(=O)NC=C1 MFOFLSYIDKCECT-UHFFFAOYSA-N 0.000 claims 1
- ZRKHPQPMAITAEP-UHFFFAOYSA-N 5-chloro-2-(2-chloro-4-fluorophenoxy)-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound ClC1=CC(F)=CC=C1OC1=CC=C(Cl)C=C1C(=O)NC1=CC(=O)NC=C1 ZRKHPQPMAITAEP-UHFFFAOYSA-N 0.000 claims 1
- AQMSMCUTJNXRFL-UHFFFAOYSA-N 5-chloro-2-(3-fluoro-4-methoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound C1=C(F)C(OC)=CC=C1OC1=CC=C(Cl)C=C1C(=O)NC1=CC(=O)NC=C1 AQMSMCUTJNXRFL-UHFFFAOYSA-N 0.000 claims 1
- IDCLDFZOZFUTLI-UHFFFAOYSA-N 5-chloro-2-(4-fluoro-2-methoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound COC1=CC(F)=CC=C1OC1=CC=C(Cl)C=C1C(=O)NC1=CC(=O)NC=C1 IDCLDFZOZFUTLI-UHFFFAOYSA-N 0.000 claims 1
- POWGSPMXXFULOC-UHFFFAOYSA-N 5-chloro-2-(4-fluoro-2-methylphenoxy)-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound CC1=CC(F)=CC=C1OC1=CC=C(Cl)C=C1C(=O)NC1=CC(=O)NC=C1 POWGSPMXXFULOC-UHFFFAOYSA-N 0.000 claims 1
- QDWZJQPXKINAHW-UHFFFAOYSA-N 5-chloro-2-(4-fluorophenoxy)-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound C1=CC(F)=CC=C1OC1=CC=C(Cl)C=C1C(=O)NC1=CC(=O)NC=C1 QDWZJQPXKINAHW-UHFFFAOYSA-N 0.000 claims 1
- MLSMJFXHDQHXSA-UHFFFAOYSA-N 5-fluoro-2-(4-methoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound C1=CC(OC)=CC=C1OC1=CC=C(F)C=C1C(=O)NC1=CC(=O)NC=C1 MLSMJFXHDQHXSA-UHFFFAOYSA-N 0.000 claims 1
- QVLYXBZUPZCZGH-UHFFFAOYSA-N 5-fluoro-2-[4-(2-methoxyethyl)phenoxy]-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound C1=CC(CCOC)=CC=C1OC1=CC=C(F)C=C1C(=O)NC1=CC(=O)NC=C1 QVLYXBZUPZCZGH-UHFFFAOYSA-N 0.000 claims 1
- QNKJHZQKTGVKRT-UHFFFAOYSA-N 5-fluoro-2-[4-[(2-methylpropan-2-yl)oxy]phenoxy]-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound C1=CC(OC(C)(C)C)=CC=C1OC1=CC=C(F)C=C1C(=O)NC1=CC(=O)NC=C1 QNKJHZQKTGVKRT-UHFFFAOYSA-N 0.000 claims 1
- FRPSWJAAGUNIRU-UHFFFAOYSA-N 5-fluoro-n-(2-oxo-1h-pyridin-4-yl)-2-(2,3,5-trimethylphenoxy)benzamide Chemical compound CC1=CC(C)=C(C)C(OC=2C(=CC(F)=CC=2)C(=O)NC2=CC(=O)NC=C2)=C1 FRPSWJAAGUNIRU-UHFFFAOYSA-N 0.000 claims 1
- PDBSQZAMVOMCHJ-UHFFFAOYSA-N 5-fluoro-n-(2-oxo-1h-pyridin-4-yl)-2-(2,4,5-trimethylphenoxy)benzamide Chemical compound C1=C(C)C(C)=CC(C)=C1OC1=CC=C(F)C=C1C(=O)NC1=CC(=O)NC=C1 PDBSQZAMVOMCHJ-UHFFFAOYSA-N 0.000 claims 1
- GNEXXGMTEPRYJA-UHFFFAOYSA-N 5-fluoro-n-(2-oxo-1h-pyridin-4-yl)-2-(4-propan-2-ylphenoxy)benzamide Chemical compound C1=CC(C(C)C)=CC=C1OC1=CC=C(F)C=C1C(=O)NC1=CC(=O)NC=C1 GNEXXGMTEPRYJA-UHFFFAOYSA-N 0.000 claims 1
- BDNWHXABGMGJIY-UHFFFAOYSA-N 5-fluoro-n-(2-oxo-1h-pyridin-4-yl)-2-(4-propoxyphenoxy)benzamide Chemical compound C1=CC(OCCC)=CC=C1OC1=CC=C(F)C=C1C(=O)NC1=CC(=O)NC=C1 BDNWHXABGMGJIY-UHFFFAOYSA-N 0.000 claims 1
- QCDCHYCAWONKAY-UHFFFAOYSA-N 5-fluoro-n-(2-oxo-1h-pyridin-4-yl)-2-[4-(2,2,2-trifluoroethoxy)phenoxy]benzamide Chemical compound C1=CNC(=O)C=C1NC(=O)C1=CC(F)=CC=C1OC1=CC=C(OCC(F)(F)F)C=C1 QCDCHYCAWONKAY-UHFFFAOYSA-N 0.000 claims 1
- MZASJKXXMQQZDQ-UHFFFAOYSA-N 5-fluoro-n-(2-oxo-1h-pyridin-4-yl)-2-[4-(4,4,4-trifluorobutoxy)phenoxy]benzamide Chemical compound C1=CNC(=O)C=C1NC(=O)C1=CC(F)=CC=C1OC1=CC=C(OCCCC(F)(F)F)C=C1 MZASJKXXMQQZDQ-UHFFFAOYSA-N 0.000 claims 1
- KYRYYQRTAJIXDA-UHFFFAOYSA-N 5-fluoro-n-(2-oxo-1h-pyridin-4-yl)-2-[4-(trifluoromethoxy)phenoxy]benzamide Chemical compound C1=CNC(=O)C=C1NC(=O)C1=CC(F)=CC=C1OC1=CC=C(OC(F)(F)F)C=C1 KYRYYQRTAJIXDA-UHFFFAOYSA-N 0.000 claims 1
- PRBIFBCFSMEHTE-UHFFFAOYSA-N 5-fluoro-n-(2-oxo-1h-pyridin-4-yl)-2-phenoxybenzamide Chemical compound C1=CNC(=O)C=C1NC(=O)C1=CC(F)=CC=C1OC1=CC=CC=C1 PRBIFBCFSMEHTE-UHFFFAOYSA-N 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 206010068065 Burning mouth syndrome Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 101000654356 Homo sapiens Sodium channel protein type 10 subunit alpha Proteins 0.000 claims 1
- 206010021639 Incontinence Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 1
- 208000002472 Morton Neuroma Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 206010059604 Radicular pain Diseases 0.000 claims 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 claims 1
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 claims 1
- 208000003728 Vulvodynia Diseases 0.000 claims 1
- 206010069055 Vulvovaginal pain Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 238000002266 amputation Methods 0.000 claims 1
- 238000011225 antiretroviral therapy Methods 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 210000003461 brachial plexus Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000002651 drug therapy Methods 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- ZXKIOHRLQVWVGA-UHFFFAOYSA-N n-(2-chloro-6-oxo-1h-pyridin-4-yl)-2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamide Chemical compound CC1=CC(F)=CC=C1OC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC(Cl)=C1 ZXKIOHRLQVWVGA-UHFFFAOYSA-N 0.000 claims 1
- OVWZROCNURWRKK-UHFFFAOYSA-N n-(2-oxo-1h-pyridin-4-yl)-2-(2-propan-2-yloxyphenoxy)-5-(trifluoromethyl)benzamide Chemical compound CC(C)OC1=CC=CC=C1OC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 OVWZROCNURWRKK-UHFFFAOYSA-N 0.000 claims 1
- UEAAJOBUYFZGHL-UHFFFAOYSA-N n-(2-oxo-1h-pyridin-4-yl)-2-(2-propoxyphenoxy)-5-(trifluoromethyl)benzamide Chemical compound CCCOC1=CC=CC=C1OC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 UEAAJOBUYFZGHL-UHFFFAOYSA-N 0.000 claims 1
- OFVXFYHEMPXWQX-UHFFFAOYSA-N n-(2-oxo-1h-pyridin-4-yl)-2-(4,4,4-trifluorobutoxy)-4-(trifluoromethyl)benzamide Chemical compound FC(F)(F)CCCOC1=CC(C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 OFVXFYHEMPXWQX-UHFFFAOYSA-N 0.000 claims 1
- KWQPEPNSBUXWMG-UHFFFAOYSA-N n-(2-oxo-1h-pyridin-4-yl)-2-(4,4,4-trifluorobutoxy)-5-(trifluoromethoxy)benzamide Chemical compound FC(F)(F)CCCOC1=CC=C(OC(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 KWQPEPNSBUXWMG-UHFFFAOYSA-N 0.000 claims 1
- QGRSBMGQNLDEPE-UHFFFAOYSA-N n-(2-oxo-1h-pyridin-4-yl)-2-(4,4,4-trifluorobutoxy)-5-(trifluoromethyl)benzamide Chemical compound FC(F)(F)CCCOC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 QGRSBMGQNLDEPE-UHFFFAOYSA-N 0.000 claims 1
- BMYFAIFEOQGCTL-UHFFFAOYSA-N n-(2-oxo-1h-pyridin-4-yl)-2-(4-propoxyphenoxy)-5-(trifluoromethyl)benzamide Chemical compound C1=CC(OCCC)=CC=C1OC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 BMYFAIFEOQGCTL-UHFFFAOYSA-N 0.000 claims 1
- JCPHCHCAKXVPLC-UHFFFAOYSA-N n-(2-oxo-1h-pyridin-4-yl)-2-[2-(trifluoromethoxy)phenoxy]-4-(trifluoromethyl)benzamide Chemical compound FC(F)(F)OC1=CC=CC=C1OC1=CC(C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 JCPHCHCAKXVPLC-UHFFFAOYSA-N 0.000 claims 1
- VWKUYSDQOUJGJG-UHFFFAOYSA-N n-(2-oxo-1h-pyridin-4-yl)-2-[2-(trifluoromethoxy)phenoxy]-5-(trifluoromethyl)benzamide Chemical compound FC(F)(F)OC1=CC=CC=C1OC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 VWKUYSDQOUJGJG-UHFFFAOYSA-N 0.000 claims 1
- INIMUMMAVCNJFA-UHFFFAOYSA-N n-(2-oxo-1h-pyridin-4-yl)-2-[4-(trifluoromethoxy)phenoxy]-4-(trifluoromethyl)benzamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1OC1=CC(C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 INIMUMMAVCNJFA-UHFFFAOYSA-N 0.000 claims 1
- UHWLWOOUNBNZHS-UHFFFAOYSA-N n-(2-oxo-1h-pyridin-4-yl)-2-[4-(trifluoromethoxy)phenoxy]-5-(trifluoromethyl)benzamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1OC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 UHWLWOOUNBNZHS-UHFFFAOYSA-N 0.000 claims 1
- AXDMEYZFXMOJQC-UHFFFAOYSA-N n-(2-oxo-1h-pyridin-4-yl)-2-phenoxy-4,6-bis(trifluoromethyl)benzamide Chemical compound C1=CNC(=O)C=C1NC(=O)C=1C(C(F)(F)F)=CC(C(F)(F)F)=CC=1OC1=CC=CC=C1 AXDMEYZFXMOJQC-UHFFFAOYSA-N 0.000 claims 1
- GHXUGFVKIDRBGU-UHFFFAOYSA-N n-(2-oxo-1h-pyridin-4-yl)-2-phenoxy-4-(trifluoromethyl)benzamide Chemical compound C=1C=CC=CC=1OC1=CC(C(F)(F)F)=CC=C1C(=O)NC=1C=CNC(=O)C=1 GHXUGFVKIDRBGU-UHFFFAOYSA-N 0.000 claims 1
- TTXHVPIJWCJKLK-UHFFFAOYSA-N n-(2-oxo-1h-pyridin-4-yl)-2-phenoxy-5-(trifluoromethoxy)benzamide Chemical compound C1=CNC(=O)C=C1NC(=O)C1=CC(OC(F)(F)F)=CC=C1OC1=CC=CC=C1 TTXHVPIJWCJKLK-UHFFFAOYSA-N 0.000 claims 1
- IJZKTKBPFIPSJP-UHFFFAOYSA-N n-(2-oxo-1h-pyridin-4-yl)-2-phenoxy-5-(trifluoromethyl)benzamide Chemical compound C1=CNC(=O)C=C1NC(=O)C1=CC(C(F)(F)F)=CC=C1OC1=CC=CC=C1 IJZKTKBPFIPSJP-UHFFFAOYSA-N 0.000 claims 1
- BSCTXVDJXNZALB-UHFFFAOYSA-N n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)-2-[6-(trifluoromethyl)pyridin-3-yl]oxybenzamide Chemical compound C=1C=C(C(F)(F)F)N=CC=1OC1=CC(C(F)(F)F)=CC=C1C(=O)NC=1C=CNC(=O)C=1 BSCTXVDJXNZALB-UHFFFAOYSA-N 0.000 claims 1
- VJQLAXPDRDVYNG-UHFFFAOYSA-N n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethoxy)-2-(3,3,3-trifluoropropoxy)benzamide Chemical compound FC(F)(F)CCOC1=CC=C(OC(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 VJQLAXPDRDVYNG-UHFFFAOYSA-N 0.000 claims 1
- GFUFBVLEJPJQBR-UHFFFAOYSA-N n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)-2-(2,3,4-trifluorophenoxy)benzamide Chemical compound FC1=C(F)C(F)=CC=C1OC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 GFUFBVLEJPJQBR-UHFFFAOYSA-N 0.000 claims 1
- PKVSOUFAHPBDDR-UHFFFAOYSA-N n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)-2-(2,3,5-trimethylphenoxy)benzamide Chemical compound CC1=CC(C)=C(C)C(OC=2C(=CC(=CC=2)C(F)(F)F)C(=O)NC2=CC(=O)NC=C2)=C1 PKVSOUFAHPBDDR-UHFFFAOYSA-N 0.000 claims 1
- FJHVYUIRHLGCLB-UHFFFAOYSA-N n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)-2-(2,4,5-trimethylphenoxy)benzamide Chemical compound C1=C(C)C(C)=CC(C)=C1OC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 FJHVYUIRHLGCLB-UHFFFAOYSA-N 0.000 claims 1
- BXOIJQLSRAKHJK-UHFFFAOYSA-N n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)-2-(3,3,3-trifluoropropoxy)benzamide Chemical compound FC(F)(F)CCOC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 BXOIJQLSRAKHJK-UHFFFAOYSA-N 0.000 claims 1
- AYQZYXKDFGQQAR-UHFFFAOYSA-N n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)-2-[4-(trifluoromethyl)phenoxy]benzamide Chemical compound C1=CC(C(F)(F)F)=CC=C1OC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 AYQZYXKDFGQQAR-UHFFFAOYSA-N 0.000 claims 1
- JLTNKDWOHFJWIN-UHFFFAOYSA-N n-(6-oxo-1h-pyridin-3-yl)-4-(trifluoromethyl)-2-[6-(trifluoromethyl)pyridin-3-yl]oxybenzamide Chemical compound C=1C=C(C(F)(F)F)N=CC=1OC1=CC(C(F)(F)F)=CC=C1C(=O)NC=1C=CC(=O)NC=1 JLTNKDWOHFJWIN-UHFFFAOYSA-N 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 208000019382 nerve compression syndrome Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 208000005198 spinal stenosis Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 208000004371 toothache Diseases 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 208000014637 trigeminal autonomic cephalalgia Diseases 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
- C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Ink Jet (AREA)
Claims (30)
1. Spoj formule I ili I’
[image]
gdje, nezavisno u svakom javljanju:
[image]
X je veza ili C1-C6 alkil gdje spomenuti C1-C6 alkil je supstituiran sa 0-6 halogena, pri čemu do dvije nesusjedne CH2 jedinice spomenutog C1-C6 alkila mogu biti zamijenjene sa -O-;
Rx je odsutan, H, ili C3-C8 cikloalifatični radikal, pri čemu do dvije nesusjedne CH2 jedinice spomenutog C3-C8 cikloalifatičnog radikala mogu biti zamijenjene sa -O- i spomenuti C3-C8 cikloalifatični radikal je supstituiran sa 0-3 supstituenta izabranih između halogena i C1-C4 alkila;
R1 je H, halogen, CN, ili C1-C6 alkil gdje spomenuti C1-C6 alkil je supstituiran sa 0-6 halogena i pri čemu do dvije nesusjedne CH2 jedinice spomenutog C1-C6 alkila mogu biti zamijenjene sa -O-;
R2 je H, halogen, CN, ili C1-C6 alkil gdje spomenuti C1-C6 alkil je supstituiran sa 0-6 halogena, pri čemu do dvije nesusjedne CH2 jedinice spomenutog C1-C6 alkila mogu biti zamijenjene sa -O-;
R3 je H, halogen, CN, ili C1-C6 alkil gdje spomenuti C1-C6 alkil je supstituiran sa 0-6 halogena, pri čemu do dvije nesusjedne CH2 jedinice spomenutog C1-C6 alkila mogu biti zamijenjene sa -O-;
R4 je H, halogen, CN, ili C1-C6 alkil gdje spomenuti C1-C6 alkil je supstituiran sa 0-6 halogena, pri čemu do dvije nesusjedne CH2 jedinice spomenutog C1-C6 alkila mogu biti zamijenjene sa -O-;
R5 je H, halogen, CN, ili -X-Rx;
R5’ je H, halogen, CN, ili -X-Rx;
R6 je H, halogen, CN, ili -X-Rx;
R6’ je H, halogen, CN, ili -X-Rx;
R7 je H, halogen, CN, ili -X-Rx;
R8 je halogen, ili C1-C6 alkil gdje spomenuti C1-C6 alkil je supstituiran sa 0-6 halogena, pri čemu do dvije nesusjedne CH2 jedinice spomenutog C1-C6 alkila mogu biti zamijenjene sa -O-;
p je cijeli broj od 0 do 3 uključujući; i
R9 je H, ili C1-C6 alkil pri čemu do dvije nesusjedne CH2 jedinice spomenutog C1-C6 alkila mogu biti zamijenjene sa -O-,
uz uvjet da spoj formule I ili I’ nije:
[image]
[image]
ili
[image]
2. Spoj prema zahtjevu 1, u kome je G
[image]
pri čemu:
R5 je H, halogen, CN, ili -X-Rx;
R5’ je H, halogen, CN, ili -X-Rx;
R6 je H, halogen, CN, ili -X-Rx;
R6’ je H, halogen, CN, ili -X-Rx;
R7 je H, halogen, CN, ili -X-Rx;
X je veza ili C1-C6 alkil gdje spomenuti C1-C6 alkil je supstituiran sa 0-6 halogena i pri čemu do dvije nesusjedne CH2 jedinice spomenutog C1-C6 alkila mogu biti zamijenjene sa -O-; i
Rx je odsutan, H, ili C3-C8 cikloalifatični radikal, pri čemu do dvije nesusjedne CH2 jedinice spomenutog C3-C8 cikloalifatičnog radikala mogu biti zamijenjene sa -O- i spomenuti C3-C8 cikloalifatični radikal je supstituiran sa 0-3 supstituenata izabranih između halogena i C1-C4 alkila, poželjno gdje je G izabran između:
[image]
[image]
3. Spoj prema zahtjevu 1, gdje R3 je C1-C6 alkil u kome spomenuti C1-C6 alkil je supstituiran sa 0-6 halogena, i/ili gdje R3 je t-butil, CF3 ili CF2CF3, i/ili:
(i) gdje je G:
[image]
i G je
[image]
ili (ii) gdje G je -X-Rx i -X-Rx je :
[image]
4. Spoj prema bilo kojem od zahtjeva 1 do 3, u kome je p 0, i/ili u kome je R9 H.
5. Spoj prema patentnom zahtjevu 1, u kome spoj: (i) ima formulu I-F ili I’-F:
[image]
u kome, nezavisno u svakom javljanju:
R3 je halogen, CN, ili C1-C6 alkil gdje spomenuti C1-C6 alkil je supstituiran sa 0-6 halogena, pri čemu do dvije nesusjedne CH2 jedinice spomenutog C1-C6 alkila mogu biti zamijenjene sa -O-;
R5 je halogen, CN, ili -X-Rx;
R7 je halogen, CN, ili -X-Rx;
X je veza ili C1-C6 alkil gdje spomenuti C1-C6 alkil je supstituiran sa 0-6 halogena i pri čemu do dvije nesusjedne CH2 jedinice spomenutog C1-C6 alkila mogu biti zamijenjene sa -O-;
Rx je odsutan, H, ili C3-C8 cikloalifatični radikal, pri čemu do dvije nesusjedne CH2 jedinice spomenutog C3-C8 cikloalifatičnog radikala mogu biti zamijenjene sa -O- i spomenuti C3-C8 cikloalifatični radikal je supstituiran sa 0-3 supstituenata izabranih između halogena i C1-C4 alkila;
R8 je halogen ili C1-C6 alkil gdje je C1-C6 alkil supstituiran sa 0-6 halogena i pri čemu do dvije nesusjedne CH2 jedinice spomenutog C1-C6 alkila mogu biti zamijenjene sa -O-;
p je cijeli broj od 0 do 3 uključujući; i
R9 je H, ili C1-C6 alkil pri čemu do dvije nesusjedne CH2 jedinice spomenutog C1-C6 alkila mogu biti zamijenjene sa -O-, poželjno gdje R3 je C1-C6 alkil pri čemu je C1-C6 alkil supstituiran sa 0-6 halogena, i/ili gdje je R3 t-butil, CF3 ili CF2CF3, i/ili gdje je A:
[image]
i/ili gdje je p 0, i/ili gdje R9 je H;
ili (ii) ima formulu I-G ili I’-G:
[image]
gdje, nezavisno u svakom javljanju:
R2 je halogen, CN, ili C1-C6 alkil gdje spomenuti C1-C6 alkil je supstituiran sa 0-6 halogena i pri čemu do dvije nesusjedne CH2 jedinice spomenutog C1-C6 alkila mogu biti zamijenjene sa -O-;
R3 je halogen, CN, ili C1-C6 alkil u kome spomenuti C1-C6 alkil je supstituiran sa 0-6 halogena i pri čemu do dvije nesusjedne CH2 jedinice spomenutog C1-C6 alkila mogu biti zamijenjene sa -O-;
R5 je halogen, CN, ili -X-Rx;
R7 je halogen, CN, ili -X-Rx;
X je veza ili C1-C6 alkil gdje spomenuti C1-C6 alkil je supstituiran sa 0-6 halogena i pri čemu do dvije nesusjedne CH2 jedinice spomenutog C1-C6 alkila mogu biti zamijenjene sa -O-;
Rx je odsutan, H, ili C3-C8 cikloalifatični radikal, pri čemu do dvije nesusjedne CH2 jedinice spomenutog C3-C8 cikloalifatičnog radikala mogu biti zamijenjene sa -O- i spomenuti C3-C8 cikloalifatični radikal je supstituiran sa 0-3 supstituenta izabrana između halogena i C1-C4 alkila;
R8 je halogen ili C1-C6 alkil gdje spomenuti C1-C6 alkil je supstituiran sa 0-6 halogena i pri čemu do dvije nesusjedne CH2 jedinice spomenutog C1-C6 alkila mogu biti zamijenjene sa -O-;
p je cijeli broj od 0 do 3 uključujući; i
R9 je H, ili C1-C6 alkil pri čemu do dvije nesusjedne CH2 jedinice spomenutog C1-C6 alkila mogu biti zamijenjene sa -O-, poželjno gdje R2 je F, Cl, CN, CF3 ili OCF3, i/ili gdje R3 je C1-C6 alkil u kome C1-C6 alkil je supstituiran sa 0-6 halogena, i/ili gdje je R3 t-butil, CF3 ili CF2CF3, i/ili gdje je prsten A:
[image]
i/ili gdje p je 0, i/ili gdje R9 je H.
6. Spoj prema zahtjevu 1, gdje je spoj izabran iz grupe koju čine:
[image]
2-(4-fluorofenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)benzamid;
[image]
2-(4-fluorofenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometil)benzamid;
[image]
2-(4-fluorofenoksi)-N-(6-okso-1,6-dihidropiridin-3-il)benzamid;
[image]
2-(4-fluorofenoksi)-N-(6-okso-1,6-dihidropiridin-3-il)-5-(trifluorometil)benzamid;
[image]
2-(4-fluorofenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-4-(trifluorometil)benzamid;
[image]
2-(4-fluorofenoksi)-N-(6-okso-1,6-dihidropiridin-3-il)-4-(trifluorometil)benzamid;
[image]
2-(2,4-difluorofenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-4-(trifluorometil)benzamid;
[image]
2-(4-(2-metoksietoksi)fenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-4-(trifluorometil)benzamid;
[image]
N-(2-okso-1,2-dihidropiridin-4-il)-2-fenoksi-4-(trifluorometil)benzamid;
[image]
2-(4-fluoro-2-metilfenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-4-(trifluorometil)benzamid;
[image]
N-(2-okso-1,2-dihidropiridin-4-il)-2-(o-toliloksi)-4-(trifluorometil)benzamid;
[image]
N-(2-okso-1,2-dihidropiridin-4-il)-2-(p-toliloksi)-4-(trifluorometil)benzamid;
[image]
4-kloro-2-(2,4-difluorofenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)benzamid;
[image]
4-kloro-2-(2-hloro-4-fluorofenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)benzamid;
[image]
4-kloro-2-(4-fluorofenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)benzamid;
[image]
4-kloro-2-(4-fluoro-2-metoksifenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)benzamid;
[image]
4-kloro-2-(2-fluoro-6-metilfenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)benzamid;
[image]
4-kloro-2-(2-kloro-6-fluorofenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)benzamid;
[image]
4-kloro-2-(2,6-difluorofenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)benzamid;
[image]
4-kloro-2-(4-fluoro-2-metilfenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)benzamid;
[image]
4-cijano-2-(4-fluorofenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)benzamid;
[image]
4-cijano-2-(4-fluoro-2-metoksifenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)benzamid;
[image]
4-cijano-2-(4-fluoro-2-metilfenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)benzamid;
[image]
2-(2,4-difluorofenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometil)benzamid;
[image]
2-(4-cijanofenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometil)benzamid;
[image]
2-(2,6-difluorofenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometil)benzamid;
[image]
N-(2-okso-1,2-dihidropiridin-4-il)-2-(p-toliloksi)-5-(trifluorometil)benzamid;
[image]
N-(2-okso-1,2-dihidropiridin-4-il)-2-(o-toliloksi)-5-(trifluorometil)benzamid;
[image]
2-(2-kloro-4-fluorofenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometil)benzamid;
[image]
2-(4-fluoro-2-metoksifenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometil)benzamid;
[image]
2-(4-fluoro-2-metilfenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometil)benzamid;
[image]
N-(2-okso-1,2-dihidropiridin-4-il)-2-fenoksi-5-(trifluorometil)benzamid;
[image]
2-(2,4-difluorofenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometoksi)benzamid;
[image]
2-(2,6-difluorofenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometoksi)benzamid;
[image]
N-(2-okso-1,2-dihidropiridin-4-il)-2-(p-toliloksi)-5-(trifluorometoksi)benzamid;
[image]
N-(2-okso-1,2-dihidropiridin-4-il)-2-(o-toliloksi)-5-(trifluorometoksi)benzamid;
[image]
2-(2-kloro-4-fluorofenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometoksi)benzamid;
[image]
2-(4-fluorofenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometoksi)benzamid;
[image]
2-(2-fluoro-6-metilfenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometoksi)benzamid;
[image]
2-(4-fluoro-2-metilfenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometoksi)benzamid;
[image]
N-(2-okso-1,2-dihidropiridin-4-il)-2-fenoksi-5-(trifluorometoksi)benzamid;
[image]
2-(4-fluoro-2-metoksifenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometoksi)benzamid;
[image]
2-(4-fluorofenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-6-(trifluorometil)benzamid;
[image]
2-(4-etoksifenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometil)benzamid;
[image]
2-(4-metoksifenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometil)benzamid;
[image]
2-(2-etoksifenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometil)benzamid;
[image]
2-(2-metoksi-4-metilfenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometil)benzamid;
[image]
2-(2-fluoro-6-metoksifenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometil)benzamid;
[image]
2-(2-kloro-4-metoksifenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometil)benzamid;
[image]
2-(4-kloro-2-metilfenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometil)benzamid;
[image]
2-(4-kloro-2-fluorofenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometil)benzamid;
[image]
2-(5-fluoro-2-metoksifenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometil)benzamid;
[image]
N-(2-okso-1,2-dihidropiridin-4-il)-2-(4-propoksifenoksi)-5-(trifluorometil)benzamid;
[image]
2-(3-fluoro-2-metoksifenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometil)benzamid;
[image]
2-(2-fluoro-4-metoksifenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometil)benzamid;
[image]
2-(5-fluoro-2-metilfenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometil)benzamid;
[image]
2-(3-fluoro-5-metoksifenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometil)benzamid;
[image]
2-(4-klorofenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometil)benzamid;
[image]
2-(3-fluoro-4-metoksifenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometil)benzamid;
[image]
N-(6-kloro-2-okso-1,2-dihidropiridin-4-il)-2-(4-fluoro-2-metilfenoksi)-5-(trifluorometil)benzamid;
[image]
2-(4-fluoro-2-metilfenoksi)-N-(6-metil-2-okso-1,2-dihidropilidin-4-il)-5-(trifluorometil)benzamid;
[image]
N-(2-okso-1,2-dihidropiridin-4-il)-2-(2-propoksifenoksi)-5-(trifluorometil)benzamid;
[image]
2-(4-metoksi-2-metilfenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometil)benzamid;
[image]
2-(2-izopropoksifenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometil)benzamid;
[image]
2-(2-klorofenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometil)benzamid;
[image]
5-kloro-2-(2-kloro-4-fluorofenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)benzamid;
[image]
5-kloro-2-(4-fluorofenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)benzamid;
[image]
5-kloro-2-(4-fluoro-2-metilfenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)benzamid;
[image]
5-kloro-2-(2,4-difluorofenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)benzamid;
[image]
5-kloro-2-(4-fluoro-2-metoksifenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)benzamid;
[image]
5-kloro-2-(3-fluoro-4-metoksifenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)benzamid;
[image]
N-(2-okso-1,2-dihidropiridin-4-il)-2-(4-(trifluorometoksi)fenoksi)-5-(trifluorometil)benzamid;
[image]
2-(4-(difluorometoksi)fenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometil)benzamid;
[image]
N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometil)-2-(4-(trifluorometil)fenoksi)benzamid;
[image]
N-(2-okso-1,2-dihidropiridin-4-il)-2-(2-(trifluorometoksi)fenoksi)-5-(trifluorometil)benzamid;
[image]
2-(2-(difluorometoksi)fenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometil)benzamid;
[image]
2-(2-kloro-4-fluorofenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-4-(trifluorometil)benzamid;
[image]
2-(4-klorofenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-4-(trifluorometil)benzamid;
[image]
N-(2-okso-1,2-dihidropiridin-4-il)-2-(4-(trifluorometoksi)fenoksi)-4-(trifluorometil)benzamid;
[image]
N-(2-okso-1,2-dihidropiridin-4-il)-2-(2-(trifluorometoksi)fenoksi)-4-(trifluorometil)benzamid;
[image]
2-(3-fluoro-4-metoksifenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-4-(trifluorometil)benzamid;
[image]
2-(4-(difluorometoksi)fenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-4-(trifluorometil)benzamid;
[image]
2-(2-(difluorometoksi)fenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-4-(trifluorometil)benzamid;
[image]
2-(2-fluoro-4-metoksifenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-4-(trifluorometil)benzamid;
[image]
2-(4-fluorofenoksi)-N-(1-(2-hidroksietil)-2-okso-1,2-dihidropiridin-4-il)-4-(trifluorometil)benzamid;
[image]
2-(4-fluoro-2-metilfenoksi)-N-(5-metil-2-okso-1,2-dihidropilidin-4-il)-4-(trifluorometil)benzamid;
[image]
2-(3-fluoro-2-metoksifenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-4-(trifluorometil)benzamid;
[image]
2-(4-fluorofenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-4-(perfluoroetil)benzamid;
[image]
2-(3-fluoro-4-metoksifenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-4-(perfluoroetil)benzamid;
[image]
N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometil)-2-(2,3,4-trifluorofenoksi)benzamid;
[image]
N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometil)-2-(2,3,5-trimetilfenoksi)benzamid;
[image]
2-(2,3-difluoro-4-metilfenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometil)benzamid;
[image]
N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometil)-2-(2,4,5-trimetilfenoksi)benzamid;
[image]
5-fluoro-N-(2-okso-1,2-dihidropiridin-4-il)-2-(2,3,5-trimetilfenoksi)benzamid;
[image]
5-fluoro-N-(2-okso-1,2-dihidropiridin-4-il)-2-fenoksibenzamid;
[image]
2-(4-ciklopropilfenoksi)-5-fluoro-N-(2-okso-1,2-dihidropiridin-4-il)benzamid;
[image]
2-(4-(terc-butoksi)fenoksi)-5-fluoro-N-(2-okso-1,2-dihidropiridin-4-il)benzamid;
[image]
2-(4-etoksifenoksi)-5-fluoro-N-(2-okso-1,2-dihidropiridin-4-il)benzamid;
[image]
5-fluoro-2-(4-izopropilfenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)benzamid;
[image]
5-fluoro-N-(2-okso-1,2-dihidropiridin-4-il)-2-(4-propoksifenoksi)benzamid;
[image]
5-fluoro-N-(2-okso-1,2-dihidropiridin-4-il)-2-(4-(trifluorometoksi)fenoksi)benzamid;
[image]
5-fluoro-2-(4-(2-metoksietil)fenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)benzamid;
[image]
2-(2-kloro-4-metoksifenoksi)-5-fluoro-N-(2-okso-1,2-dihidropiridin-4-il)benzamid;
[image]
5-fluoro-2-(4-metoksifenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)benzamid;
[image]
5-fluoro-N-(2-okso-1,2-dihidropiridin-4-il)-2-(2,4,5-trimetilfenoksi)benzamid;
[image]
2-(4-fluoro-2-metilfenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometil)benzamid;
[image]
5-fluoro-N-(2-okso-1,2-dihidropiridin-4-il)-2-(4-(2,2,2-trifluoroetoksi)fenoksi)benzamid;
[image]
2-(4-(ciklopropilmetoksi)fenoksi)-5-fluoro-N-(2-okso-1,2-dihidropiridin-4-il)benzamid;
[image]
4-kloro-2-(2-kloro-4-fluorofenoksi)-5-fluoro-N-(2-okso-1,2-dihidropiridin-4-il)benzamid;
[image]
2-(2-kloro-3-fluoro-4-metoksifenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-4-(trifluorometil)benzamid;
[image]
2-(4-fluoro-2-metoksifenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-4-(perfluoroetil)benzamid;
[image]
2-(4-fluoro-2-metilfenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-4-(perfluoroetil)benzamid;
[image]
4,5-dikloro-2-(4-fluorofenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)benzamid;
[image]
4,5-dikloro-2-(4-fluoro-2-metoksifenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)benzamid;
[image]
4,5-dikloro-2-(3-fluoro-4-metoksifenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)benzamid;
[image]
2-(izopentiloksi)-N-(2-okso-1,2-dihidropiridin-4-il)-4-(trifluorometil)benzamid;
[image]
2-izobutoksi-N-(2-okso-1,2-dihidropiridin-4-il)-4-(trifluorometil)benzamid;
[image]
2-((2R)-biciklo[2.2.1]heptan-2-iloksi)-N-(2-okso-1,2-dihidropiridin-4-il)-4-(trifluorometil)benzamid;
[image]
2-((1-metilciklopropil)metoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-4-(trifluorometil)benzamid;
[image]
2-(ciklopentilmetoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-4-(trifluorometil)benzamid;
[image]
N-(2-okso-1,2-dihidropiridin-4-il)-2-((tetrahidrofuran-3-il)metoksi)-4-(trifluorometil)benzamid;
[image]
2-ciklobutoksi-N-(2-okso-1,2-dihidropiridin-4-il)-4-(trifluorometil)benzamid;
[image]
N-(2-okso-1,2-dihidropiridin-4-il)-2-(4,4,4-trifluorobutoksi)-4-(trifluorometil)benzamid;
[image]
2-((2,2-dimetilciklopropil)metoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-4-(trifluorometil)benzamid;
[image]
2-((1R,5S)-biciklo[3.1.0]heksan-3-iloksi)-N-(2-okso-1,2-dihidropiridin-4-il)-4-(trifluorometil)benzamid;
[image]
2-((2,2-difluorociklopropil)metoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-4-(trifluorometil)benzamid;
[image]
2-(biciklo[2.2.1]heptan-2-iloksi)-N-(2-okso-1,2-dihidropiridin-4-il)-4-(trifluorometil)benzamid;
[image]
2-(cikloheksiloksi)-N-(2-okso-1,2-dihidropiridin-4-il)-4-(trifluorometil)benzamid;
[image]
4-kloro-N-(2-okso-1,2-dihidropiridin-4-il)-2-(4,4,4-trifluorobutoksi)benzamid;
[image]
2-(ciklopentilmetoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometil)benzamid;
[image]
2-izobutoksi-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometil)benzamid;
[image]
N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometil)-2-(3,3,3-trifluoropropoksi)benzamid;
[image]
N-(2-okso-1,2-dihidropiridin-4-il)-2-(4,4,4-trifluorobutoksi)-5-(trifluorometil)benzamid;
[image]
2-((2,2-dimetilciklopropil)metoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometil)benzamid;
[image]
2-((1R,5S)-biciklo[3.1.0]heksan-3-iloksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometil)benzamid;
[image]
2-(ciklopentilmetoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometoksi)benzamid;
[image]
2-(cikloheksiloksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometoksi)benzamid;
[image]
N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometoksi)-2-(3,3,3-trifluoropropoksi)benzamid;
[image]
N-(2-okso-1,2-dihidropiridin-4-il)-2-(4,4,4-trifluorobutoksi)-5-(trifluorometoksi)benzamid;
[image]
2-((2,2-dimetilciklopropil)metoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometoksi)benzamid;
[image]
4-(terc-butil)-N-(2-okso-1,2-dihidropiridin-4-il)-2-((6-(trifluorometil)piridin-3-il)oksi)benzamid;
[image]
4-(terc-butil)-N-(6-okso-1,6-dihidropiridin-3-il)-2-((6-(trifluorometil)piridin-3-il)oksi)benzamid;
[image]
4-kloro-N-(2-okso-1,2-dihidropiridin-4-il)-2-((6-(trifluorometil)piridin-3-il)oksi)benzamid;
[image]
N-(2-okso-1,2-dihidropiridin-4-il)-4-(trifluorometil)-2-((6-(trifluorometil)piridin-3-il)oksi)benzamid;
[image]
N-(6-okso-1,6-dihidropiridin-3-il)-4-(trifluorometil)-2-((6-(trifluorometil)piridin-3-il)oksi)benzamid;
[image]
2-((6-metilpiridin-3-il)oksi)-N-(2-okso-1,2-dihidropiridin-4-il)-4-(trifluorometil)benzamid;
[image]
2-((2-metilpiridin-3-il)oksi)-N-(2-okso-1,2-dihidropiridin-4-il)-4-(trifluorometil)benzamid;
[image]
4-(terc-butil)-N-(1-metil-2-okso-1,2-dihidropiridin-4-il)-2-((6-(trifluorometil)piridin-3-il)oksi)benzamid;
[image]
4-(terc-butil)-N-(1-metil-6-okso-1,6-dihidropiridin-3-il)-2-((6-(trifluorometil)piridin-3-il)oksi)benzamid;
[image]
2-((2-metilpiridin-3-il)oksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometil)benzamid;
[image]
2-((2-metilpiridin-3-il)oksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometoksi)benzamid;
[image]
2-(2,4-difluorofenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-4,6-bis(trifluorometil)benzamid;
[image]
2-(4-fluoro-2-metilfenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-4,6-bis(trifluorometil)benzamid;
[image]
2-(4-fluoro-2-metoksifenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-4,6-bis(trifluorometil)benzamid;
[image]
2-(4-fluorofenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-4,6-bis(trifluorometil)benzamid;
[image]
N-(2-okso-1,2-dihidropiridin-4-il)-2-fenoksi-4,6-bis(trifluorometil)benzamid;
[image]
2-(4-fluoro-2-(hidroksimetil)fenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-4-(trifluorometil)benzamid;
[image]
2-(4-fluoro-2-metoksifenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-4-(trifluorometil)benzamid;
[image]
2-((5-fluoro-2-hidroksibenzil)oksi)-N-(2-okso-1,2-dihidropiridin-4-il)-4-(trifluorometil)benzamid; i
[image]
5-fluoro-N-(2-okso-1,2-dihidropiridin-4-il)-2-(4-(4,4,4-trifluorobutoksi)fenoksi)benzamid.
7. Spoj prema zahtjevu 1, što je spoj:
[image]
2-(4-fluoro-2-metilfenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-4-(trifluorometil)benzamid.
8. Spoj prema zahtjevu 1, što je spoj:
[image]
2-(4-fluorofenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-5-(trifluorometil)benzamid.
9. Spoj prema zahtjevu 1, što je spoj:
[image]
4-kloro-2-(4-fluoro-2-metilfenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)benzamid.
10. Spoj prema zahtjevu 1, što je spoj:
[image]
2-(4-fluoro-2-metoksifenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-4-(perfluoroetil)benzamid.
11. Spoj prema zahtjevu 1, što je spoj:
[image]
4,5-dikloro-2-(4-fluoro-2-metoksifenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)benzamid.
12. Farmaceutski sastav koji sadrži terapeutski efikasnu količinu spoja prema bilo kojem od zahtjeva 1 do 11 i jedan ili više farmaceutski prihvatljivih nosača ili nosećih sredstava.
13. Farmaceutski sastav prema zahtjevu 12, što je spoj:
[image]
2-(4-fluoro-2-metilfenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-4-(trifluorometil)benzamid.
14. Farmaceutski sastav prema zahtjevu 12, što je spoj:
[image]
4-kloro-2-(4-fluoro-2-metilfenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)benzamid.
15. Farmaceutski sastav prema zahtjevu 12, što je spoj:
[image]
4,5-dikloro-2-(4-fluoro-2-metoksifenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)benzamid.
16. Spoj prema bilo kojem od zahtjeva 1 do 11 ili farmaceutski sastav prema bilo kojem od zahtjeva 12 do 15 za upotrebu u postupku inhibiranja naponski zavisnih natrijevih kanala kod subjekta za liječenje ili ublažavanje jačine boli kod spomenutog subjekta, poželjno gdje je naponski zavisni natrijev kanal Nav1.8.
17. Spoj za upotrebu prema zahtjevu 16, pri čemu je spoj:
[image]
2-(4-fluoro-2-metilfenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-4-(trifluorometil)benzamid.
18. Spoj za upotrebu prema zahtjevu 16, pri čemu je spoj:
[image]
4-kloro-2-(4-fluoro-2-metilfenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)benzamid.
19. Spoj za upotrebu prema zahtjevu 16, pri čemu je spoj:
[image]
4,5-dikloro-2-(4-fluoro-2-metoksifenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)benzamid.
20. Spoj prema bilo kojem od zahtjeva 1 do 11 ili farmaceutski sastav prema bilo kojem od zahtjeva 12 do 15 za upotrebu u liječenju ili ublažavanju jačine kod subjekta: (i) kronične boli, boli u crijevima, neuropatske boli, mišićno-koštane boli, akutne boli, upalne boli, boli uslijed raka, idiopatske boli, postoperativne boli, multiple skleroze, Charcot-Marie-Toothovog sindroma, inkotinencije ili srčane aritmije, poželjno gdje bol crijeva obuhvaća bol uslijed upalne bolesti crijeva, Crohnovu bolest ili bol uslijed intersticijskog cistitisa, ili gdje neuropatska bol obuhvaća postherpesnu neuralgiju, dijabetičnu neuralgiju, bolnu senzornu neuropatiju u vezi sa HIV-om, trigeminalnu neuralgiju, sindrom pečenja u ustima, bol poslije amputacije, fantomsku bol, bolni neurom; traumatični neurom; Mortonov neurom; povrede uklještenja živca, spinalnu stenozu, sindrom karpalnog tunela, radikularna bol, šijatička bol; avulziju živca, nasilno odvajanje brahijalnog pleksusa; kompleksni sidrom regionalne boli, neuralgiju izazvanu terapijom lijekovima, neuralgiju izazvanu kemoterapijom raka, neuralgiju izazvanu antiretroviralnom terapijom; bol poslije povrede kralježnične moždine, idiopatsku neuropatiju kratkih vlakana, idiopatsku senzornu neuropatiju ili trigeminalnu autonomnu cefalalgiju, ili gdje mišićno-koštana bol obuhvaća bol uslijed oesteoartritisa, bol u leđima, bol uslijed hladnoće, bol uslijed opekotine ili bol zuba, ili gdje upalna bol obuhvaća bol uslijed reumatoidnog artritisa ili vulvodiniju, ili gdje idiopatska bol obuhvaća bol uslijed fibromijalgije ili (ii) visceralne boli.
21. Spoj ili farmaceutski sastav za upotrebu prema zahtjevu 20, u kojoj spoj ili farmaceutski sastav je za upotrebu u: (i) postupku liječenja ili ublažavanja ozbiljnosti neuropatske boli kod subjekta, pri čemu neuropatska bol obuhvaća idiopatsku neuropatiju kratkih vlakana; (ii) postupku liječenja ili ublažavanja ozbiljnosti mišićno-koštane boli kod subjekta, pri čemu mišićno-koštana bol obuhvaća bol uslijed osteoartritisa; (iii) postupku liječenja ili ublažavanja ozbiljnosti akutne boli kod subjekta, pri čemu akutna bol obuhvaća akutnu postoperativnu bol; (iv) postupku liječenja ili ublažavanja ozbiljnosti postoperativne boli kod subjekta; (v) postupku liječenja ili ublažavanja ozbiljnosti neuropatske boli kod subjekta, pri čemu neuropatska bol obuhvaća postherpesnu neuralgiju; (vi) postupku liječenja ili ublažavanja ozbiljnosti neuropatske boli kod subjekta; (vii) postupku liječenja ili ublažavanja ozbiljnosti mišićno-koštane boli kod subjekta; (viii) postupku liječenja ili ublažavanja ozbiljnosti akutne boli kod subjekta; ili (ix) postupku liječenja ili ublažavanja ozbiljnosti visceralne boli kod subjekta.
22. Spoj za upotrebu prema zahtjevu 20 ili 21, pri čemu je spoj:
[image]
2-(4-fluoro-2-metilfenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)-4-(trifluorometil)benzamid.
23. Spoj za upotrebu prema zahtjevu 20 ili 21, pri čemu je spoj:
[image]
4-kloro-2-(4-fluoro-2-metilfenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)benzamid.
24. Spoj za upotrebu prema zahtjevu 20 ili 21, pri čemu je spoj:
[image]
4,5-dikloro-2-(4-fluoro-2-metoksifenoksi)-N-(2-okso-1,2-dihidropiridin-4-il)benzamid.
25. Spoj za upotrebu prema bilo kojem od zahtjeva 22 do 24, pri čemu je spoj za upotrebu u postupku liječenja ili ublažavanja ozbiljnosti akutne boli kod subjekta.
26. Spoj za upotrebu prema bilo kojem od zahtjeva 22 do 24, pri čemu je spoj za upotrebu u postupku liječenja ili ublažavanja ozbiljnosti postoperativne boli kod subjekta.
27. Spoj za upotrebu prema bilo kojem od zahtjeva 22 do 24, pri čemu je spoj za upotrebu u postupku liječenja ili ublažavanja ozbiljnosti neuropatske boli kod subjekta.
28. Spoj za upotrebu prema bilo kojem od zahtjeva 22 do 24, pri čemu je spoj za upotrebu u postupku liječenja ili ublažavanja ozbiljnosti kronične boli kod subjekta.
29. Spoj za upotrebu prema bilo kojem od zahtjeva 22 do 24, pri čemu je spoj za upotrebu u postupku liječenja ili ublažavanja ozbiljnosti boli uslijed osteoartritisa kod subjekta.
30. Spoj ili farmaceutski sastav za upotrebu prema bilo kojem od zahtjeva 16 do 29, pri čemu je spomenuti subjekt liječen sa jedim ili više dodatnih terapeutskih sredstava davanih istovremeno sa, prije ili poslije tretmana sa spojem ili farmaceutski prihvatljivom soli ili farmaceutskim sastavom.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361759059P | 2013-01-31 | 2013-01-31 | |
EP17152492.9A EP3239134B1 (en) | 2013-01-31 | 2014-01-29 | Pyridone amides as modulators of sodium channels |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20210349T1 true HRP20210349T1 (hr) | 2021-04-16 |
Family
ID=50073531
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20170787TT HRP20170787T1 (hr) | 2013-01-31 | 2017-05-26 | Piridon amidi kao modulatori natrijevih kanala |
HRP20210349TT HRP20210349T1 (hr) | 2013-01-31 | 2021-03-01 | Piridon amidi kao modulatori natrijevih kanala |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20170787TT HRP20170787T1 (hr) | 2013-01-31 | 2017-05-26 | Piridon amidi kao modulatori natrijevih kanala |
Country Status (34)
Country | Link |
---|---|
US (6) | US9051270B2 (hr) |
EP (3) | EP3239134B1 (hr) |
JP (4) | JP6389194B2 (hr) |
KR (2) | KR102295748B1 (hr) |
CN (2) | CN108164457B (hr) |
AP (1) | AP2015008633A0 (hr) |
AR (1) | AR094667A1 (hr) |
AU (3) | AU2014212509B2 (hr) |
BR (1) | BR112015018289A2 (hr) |
CA (1) | CA2898866C (hr) |
CL (1) | CL2015002147A1 (hr) |
CY (1) | CY1119163T1 (hr) |
DK (2) | DK2953931T3 (hr) |
ES (2) | ES2626555T3 (hr) |
GE (2) | GEP20217286B (hr) |
HK (2) | HK1217693A1 (hr) |
HR (2) | HRP20170787T1 (hr) |
HU (2) | HUE053448T2 (hr) |
IL (1) | IL240195B (hr) |
LT (2) | LT2953931T (hr) |
MX (2) | MX2021003687A (hr) |
NZ (2) | NZ710270A (hr) |
PE (2) | PE20151781A1 (hr) |
PH (1) | PH12015501661A1 (hr) |
PL (2) | PL2953931T3 (hr) |
PT (2) | PT3239134T (hr) |
RS (2) | RS61503B1 (hr) |
RU (1) | RU2662223C2 (hr) |
SG (2) | SG10201706206PA (hr) |
SI (2) | SI3239134T1 (hr) |
TW (2) | TWI655187B (hr) |
UA (1) | UA120589C2 (hr) |
UY (1) | UY35288A (hr) |
WO (1) | WO2014120808A1 (hr) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9481677B2 (en) | 2011-10-31 | 2016-11-01 | Xenon Pharmaceuticals Inc. | Biaryl ether sulfonamides and their use as therapeutic agents |
WO2013064983A1 (en) | 2011-10-31 | 2013-05-10 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
AR091112A1 (es) | 2012-05-22 | 2015-01-14 | Genentech Inc | Benzamidas n-sustituidas como inhibidores de los canales de sodio nav1.7 |
EP2870138B1 (en) | 2012-07-06 | 2018-08-22 | Genentech, Inc. | N-substituted benzamides and methods of use thereof |
PL2953931T3 (pl) | 2013-01-31 | 2017-09-29 | Vertex Pharmaceuticals Incorporated | Pirydonoamidy jako modulatory kanałów sodowych |
US9139529B2 (en) | 2013-01-31 | 2015-09-22 | Vertex Pharmaceuticals Incorporated | Substituted quinoxalines as sodium channel modulators |
KR20150131233A (ko) | 2013-03-14 | 2015-11-24 | 제넨테크, 인크. | 치환된 트리아졸로피리딘 및 이의 사용 방법 |
JP6227112B2 (ja) | 2013-03-15 | 2017-11-08 | ジェネンテック, インコーポレイテッド | 置換ベンゾオキサゾールとその使用方法 |
US11203571B2 (en) | 2013-07-19 | 2021-12-21 | Vertex Pharmaceuticals Incorporated | Sulfonamides as modulators of sodium channels |
EP3074377B1 (en) | 2013-11-27 | 2018-10-17 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
NZ760006A (en) * | 2013-12-13 | 2022-07-29 | Vertex Pharma | Prodrugs of pyridone amides useful as modulators of sodium channels |
US10005724B2 (en) | 2014-07-07 | 2018-06-26 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
AU2016268120A1 (en) | 2015-05-22 | 2017-11-30 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
WO2017035271A1 (en) | 2015-08-27 | 2017-03-02 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
JP6987746B2 (ja) | 2015-09-28 | 2022-01-05 | ジェネンテック, インコーポレイテッド | 治療用化合物及びその使用方法 |
CN108495851A (zh) | 2015-11-25 | 2018-09-04 | 基因泰克公司 | 取代的苯甲酰胺及其使用方法 |
MX2018009870A (es) | 2016-02-15 | 2018-11-29 | Cemm Forschungszentrum Fuer Molekulare Medizin Gmbh | Inhibidores de taf1 para la terapia del cancer. |
WO2017147147A1 (en) * | 2016-02-23 | 2017-08-31 | PixarBio Corporation | Compositions comprising nav1.7 selective inhibitors for treating acute, post-operative, or chronic pain and methods of using the same |
CN109071426A (zh) | 2016-03-30 | 2018-12-21 | 基因泰克公司 | 取代的苯甲酰胺及其使用方法 |
JP2019532077A (ja) | 2016-10-17 | 2019-11-07 | ジェネンテック, インコーポレイテッド | 治療用化合物及びその使用方法 |
CN110546148A (zh) | 2017-03-24 | 2019-12-06 | 基因泰克公司 | 作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物 |
UA124857C2 (uk) * | 2017-05-16 | 2021-12-01 | Вертекс Фармасьютикалз Інкорпорейтед | Дейтеровані піридонаміди і їх проліки як модулятори натрієвих каналів |
PE20201164A1 (es) | 2017-07-11 | 2020-10-28 | Vertex Pharma | Carboxamidas como moduladores de los canales de sodio |
CN111918650A (zh) | 2018-02-12 | 2020-11-10 | 沃泰克斯药物股份有限公司 | 治疗疼痛的方法 |
TW202000651A (zh) | 2018-02-26 | 2020-01-01 | 美商建南德克公司 | 治療性組成物及其使用方法 |
US10947251B2 (en) | 2018-03-30 | 2021-03-16 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
CA3117927A1 (en) | 2018-11-02 | 2020-05-07 | Merck Sharp & Dohme Corp. | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors |
CA3125244A1 (en) * | 2019-01-04 | 2020-07-09 | Jiangsu Hengrui Medicine Co., Ltd. | 6-oxo-1,6-dihydropyridazine derivative, preparation method therefor and medical use thereof |
US20230062053A1 (en) | 2019-01-10 | 2023-03-02 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
WO2020146612A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
WO2020151728A1 (zh) * | 2019-01-25 | 2020-07-30 | 江苏恒瑞医药股份有限公司 | 2-氧代-1,2-二氢吡啶类衍生物、其制备方法及其在医药上的应用 |
BR112021014178A2 (pt) * | 2019-02-20 | 2021-09-21 | Jiangsu Hengrui Medicine Co., Ltd. | Derivado de pró-fármaco de 6-oxo-1,6-diidropiridazina, método de preparação para o mesmo e aplicação do mesmo na medicina |
WO2020176763A1 (en) | 2019-02-27 | 2020-09-03 | Vertex Pharmaceuticals Incorporated | Dosage form comprising prodrug of na 1.8 sodium channel inhibitor |
WO2020219867A1 (en) | 2019-04-25 | 2020-10-29 | Vertex Pharmaceuticals Incorporated | Pyridone amide co-crystal compositions for the treatment of pain |
WO2021018165A1 (zh) * | 2019-07-30 | 2021-02-04 | 江苏恒瑞医药股份有限公司 | 吡啶苯甲酰胺类衍生物、其制备方法及其在医药上的应用 |
CN112390745B (zh) * | 2019-08-19 | 2022-10-21 | 江苏恒瑞医药股份有限公司 | 吡啶烟酰胺类衍生物、其制备方法及其在医药上的应用 |
WO2021032074A1 (zh) * | 2019-08-19 | 2021-02-25 | 江苏恒瑞医药股份有限公司 | 苯甲酰胺稠芳环类衍生物、其制备方法及其在医药上的应用 |
CA3150400A1 (en) * | 2019-09-12 | 2021-03-18 | Shanghai Jemincare Pharmaceuticals Co., Ltd | PYRIDINE OXYNITRIDE, METHOD FOR PREPARATION AND USE |
US11834441B2 (en) | 2019-12-06 | 2023-12-05 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofurans as modulators of sodium channels |
CN113045487A (zh) * | 2019-12-27 | 2021-06-29 | 明慧医药(上海)有限公司 | 一种选择性钠通道调节剂及其制备和应用 |
CN114437062B (zh) * | 2020-04-30 | 2024-05-17 | 成都海博为药业有限公司 | 一种可作为钠通道调节剂的化合物及其用途 |
JP7323723B2 (ja) | 2020-06-17 | 2023-08-08 | メルク・シャープ・アンド・ドーム・エルエルシー | Nav1.8阻害剤としての2-オキソイミダゾリジン-4-カルボキサミド |
CN113880771B (zh) * | 2020-07-03 | 2023-09-19 | 福建盛迪医药有限公司 | 一种选择性Nav抑制剂的结晶形式及其制备方法 |
CN111808019B (zh) * | 2020-09-08 | 2020-11-27 | 上海济煜医药科技有限公司 | 一种并环化合物及其应用 |
CN114031518B (zh) | 2020-12-08 | 2023-08-18 | 成都海博为药业有限公司 | 一种苄胺或苄醇衍生物及其用途 |
EP4334293A1 (en) | 2021-05-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors |
CN117813302A (zh) | 2021-06-04 | 2024-04-02 | 沃泰克斯药物股份有限公司 | 经取代的四氢呋喃-2-甲酰胺作为钠通道调节剂 |
WO2022256708A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide |
EP4347031A1 (en) | 2021-06-04 | 2024-04-10 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
JP2024520643A (ja) | 2021-06-04 | 2024-05-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | ナトリウムチャネルの調節因子としてのヒドロキシ及び(ハロ)アルコキシ置換テトラヒドロフラン |
AU2022285758A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
EP4347584A1 (en) | 2021-06-04 | 2024-04-10 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels |
AR126669A1 (es) | 2021-08-02 | 2023-11-01 | Eurofarma Laboratorios S A | COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS |
AR126670A1 (es) | 2021-08-02 | 2023-11-01 | Eurofarma Laboratorios S A | COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS |
WO2023160509A1 (zh) * | 2022-02-25 | 2023-08-31 | 中国科学院上海药物研究所 | 脒类衍生化合物及其制备方法和用途 |
US20230373925A1 (en) | 2022-04-22 | 2023-11-23 | Vertex Pharma | Heteroaryl compounds for the treatment of pain |
WO2023205465A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
US20230382910A1 (en) | 2022-04-22 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
WO2023205468A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
WO2023211990A1 (en) | 2022-04-25 | 2023-11-02 | Siteone Therapeutics, Inc. | Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain |
CN116947713A (zh) * | 2022-04-25 | 2023-10-27 | 中国科学院上海药物研究所 | 并环类化合物及其应用 |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH598252A5 (hr) | 1974-01-04 | 1978-04-28 | Hoffmann La Roche | |
GB1447583A (en) * | 1974-02-04 | 1976-08-25 | Ici Ltd | Xanthene derivatives |
US4086350A (en) * | 1974-11-06 | 1978-04-25 | Smithkline Corporation | Pharmaceutical compositions and method of producing anti-psychotic activity without extrapyramidal symptoms |
GB1543964A (en) * | 1976-04-08 | 1979-04-11 | Ici Ltd | Method of antagonising herbicides on soyabean and cotton |
US5281620A (en) * | 1986-12-23 | 1994-01-25 | Cancer Research Campaign Technology Limited | Compounds having antitumor and antibacterial properties |
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
JP3285391B2 (ja) * | 1992-09-01 | 2002-05-27 | 日本化学工業株式会社 | 2−フェノキシ安息香酸の製造法 |
US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
AU7712000A (en) | 1999-09-24 | 2001-04-24 | Johns Hopkins University School Of Medicine, The | Methods for identifying an agent that corrects defective protein folding |
JP2003034671A (ja) * | 2001-05-17 | 2003-02-07 | Nippon Nohyaku Co Ltd | ベンズアミド誘導体及び農園芸用薬剤並びにその使用方法 |
ES2334990T3 (es) | 2002-02-14 | 2010-03-18 | Pharmacia Corporation | Piridinonas sustituidas como moduladores de p38 map quinasa. |
TW200524888A (en) * | 2003-08-08 | 2005-08-01 | Vertex Pharma | Compositions useful as inhibitors of voltage-gated ion channels |
BRPI0414130B8 (pt) * | 2003-09-03 | 2021-05-25 | Askat Inc | compostos de fenilamida ou piridilamida, seu uso e composições farmacêuticas que os compreendem. |
EP1802580A2 (en) | 2004-07-23 | 2007-07-04 | Pfizer, Inc. | Pyridine derivatives |
AU2006254809B2 (en) | 2005-06-09 | 2012-03-15 | Vertex Pharmaceuticals Incorporated | Indane derivatives as modulators of ion channels |
JP2009507851A (ja) | 2005-09-09 | 2009-02-26 | バーテックス ファーマシューティカルズ インコーポレイテッド | 電位型イオンチャネルの調節因子としての二環式誘導体 |
JP2009511599A (ja) | 2005-10-12 | 2009-03-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | 電位依存性イオンチャネルの調整剤としてのビフェニル誘導体 |
MX2008013194A (es) * | 2006-04-11 | 2008-12-01 | Vertex Pharma | Composiciones utiles como inhibidores de canales de sodio regulados por voltaje. |
CN101675040A (zh) | 2007-05-03 | 2010-03-17 | 辉瑞有限公司 | 作为钠通道调节剂的2-吡啶甲酰胺衍生物 |
NZ581309A (en) | 2007-05-25 | 2012-02-24 | Vertex Pharma | Ion channel modulators and methods of use |
KR20100066583A (ko) * | 2007-10-11 | 2010-06-17 | 버텍스 파마슈티칼스 인코포레이티드 | 전압-개폐 나트륨 채널의 억제제로서 유용한 아미드 |
EP2212290B1 (en) * | 2007-10-11 | 2014-12-03 | Vertex Pharmaceuticals Incorporated | Aryl amides useful as inhibitors of voltage-gated sodium channels |
JP5555169B2 (ja) * | 2007-10-11 | 2014-07-23 | バーテックス ファーマシューティカルズ インコーポレイテッド | 電位開口型ナトリウムチャネルの阻害剤として有用なヘテロアリールアミド |
CA2703915C (en) * | 2007-10-31 | 2015-02-24 | Merck Sharp & Dohme Corp. | P2x3 receptor antagonists for treatment of pain |
EP2382202A1 (en) | 2008-12-23 | 2011-11-02 | F. Hoffmann-La Roche AG | Dihydropyridone amides as p2x7 modulators |
CA2761639C (en) * | 2009-05-29 | 2016-06-07 | Raqualia Pharma Inc. | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers |
AR077033A1 (es) * | 2009-06-11 | 2011-07-27 | Hoffmann La Roche | Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas |
AU2011227511B2 (en) | 2010-03-15 | 2014-02-20 | Amgen Inc. | Spiro-tetracyclic ring compounds as Beta - secretase modulators |
US8598164B2 (en) | 2010-05-06 | 2013-12-03 | Vertex Pharmaceuticals Incorporated | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels |
WO2012050918A2 (en) | 2010-09-29 | 2012-04-19 | Presidio Pharmaceutical, Inc. | Tricyclic fused ring inhibitors of hepatitis c |
SI2670752T1 (sl) | 2011-02-02 | 2016-10-28 | Vertex Pharmaceuticals Incorporated | Pirolopirazin-spirociklični piperidin amidi kot modulatorji ionskih kanalčkov |
WO2012112462A1 (en) | 2011-02-15 | 2012-08-23 | Amgen Inc. | Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use |
EP2675812B1 (en) | 2011-02-18 | 2017-08-30 | Vertex Pharmaceuticals Incorporated | Chroman - spirocyclic piperidine amides as modulators of ion channels |
AU2012229187B2 (en) | 2011-03-14 | 2016-11-10 | Vertex Pharmaceuticals Incorporated | Morpholine-spirocyclic piperidine amides as modulators of ion channels |
WO2012122716A1 (en) | 2011-03-17 | 2012-09-20 | Merck Sharp & Dohme Corp. | Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases |
EP2691075A1 (en) | 2011-03-29 | 2014-02-05 | Sanofi | Otamixaban formulations with improved stability |
JP5730398B2 (ja) | 2011-08-10 | 2015-06-10 | 三菱電機株式会社 | 誘導加熱調理器及びそのプログラム |
CN102584774B (zh) | 2011-12-22 | 2014-08-06 | 合肥工业大学 | 一种呫吨酮类衍生物及其用途 |
CN104169286B (zh) | 2012-03-06 | 2016-06-08 | 辉瑞大药厂 | 用于治疗增殖性疾病的大环衍生物 |
CN102659628B (zh) | 2012-04-26 | 2014-07-02 | 四川大学 | 含芳酰胺的邻苯二甲腈单体及其合成方法和用其固化制备的聚邻苯二甲腈树脂 |
PL2953931T3 (pl) | 2013-01-31 | 2017-09-29 | Vertex Pharmaceuticals Incorporated | Pirydonoamidy jako modulatory kanałów sodowych |
TWI659945B (zh) | 2013-01-31 | 2019-05-21 | 維泰克斯製藥公司 | 作爲鈉通道調節劑之醯胺 |
US9139529B2 (en) | 2013-01-31 | 2015-09-22 | Vertex Pharmaceuticals Incorporated | Substituted quinoxalines as sodium channel modulators |
TWI606048B (zh) | 2013-01-31 | 2017-11-21 | 帝人製藥股份有限公司 | 唑苯衍生物 |
US11203571B2 (en) | 2013-07-19 | 2021-12-21 | Vertex Pharmaceuticals Incorporated | Sulfonamides as modulators of sodium channels |
NZ760006A (en) | 2013-12-13 | 2022-07-29 | Vertex Pharma | Prodrugs of pyridone amides useful as modulators of sodium channels |
PE20201164A1 (es) | 2017-07-11 | 2020-10-28 | Vertex Pharma | Carboxamidas como moduladores de los canales de sodio |
CN111918650A (zh) | 2018-02-12 | 2020-11-10 | 沃泰克斯药物股份有限公司 | 治疗疼痛的方法 |
-
2014
- 2014-01-29 PL PL14704053T patent/PL2953931T3/pl unknown
- 2014-01-29 NZ NZ710270A patent/NZ710270A/en unknown
- 2014-01-29 CN CN201810153601.4A patent/CN108164457B/zh active Active
- 2014-01-29 MX MX2021003687A patent/MX2021003687A/es unknown
- 2014-01-29 EP EP17152492.9A patent/EP3239134B1/en active Active
- 2014-01-29 HU HUE17152492A patent/HUE053448T2/hu unknown
- 2014-01-29 DK DK14704053.9T patent/DK2953931T3/en active
- 2014-01-29 SG SG10201706206PA patent/SG10201706206PA/en unknown
- 2014-01-29 LT LTEP14704053.9T patent/LT2953931T/lt unknown
- 2014-01-29 CA CA2898866A patent/CA2898866C/en active Active
- 2014-01-29 KR KR1020217007028A patent/KR102295748B1/ko active IP Right Grant
- 2014-01-29 JP JP2015556109A patent/JP6389194B2/ja active Active
- 2014-01-29 LT LTEP17152492.9T patent/LT3239134T/lt unknown
- 2014-01-29 TW TW103103691A patent/TWI655187B/zh active
- 2014-01-29 CN CN201480011392.XA patent/CN105026373B/zh active Active
- 2014-01-29 DK DK17152492.9T patent/DK3239134T3/da active
- 2014-01-29 PE PE2015001572A patent/PE20151781A1/es active IP Right Grant
- 2014-01-29 PL PL17152492T patent/PL3239134T3/pl unknown
- 2014-01-29 GE GEAP201413922A patent/GEP20217286B/en unknown
- 2014-01-29 RS RS20210235A patent/RS61503B1/sr unknown
- 2014-01-29 ES ES14704053T patent/ES2626555T3/es active Active
- 2014-01-29 PT PT171524929T patent/PT3239134T/pt unknown
- 2014-01-29 WO PCT/US2014/013652 patent/WO2014120808A1/en active Application Filing
- 2014-01-29 SI SI201431756T patent/SI3239134T1/sl unknown
- 2014-01-29 PE PE2019001687A patent/PE20191495A1/es unknown
- 2014-01-29 AR ARP140100281A patent/AR094667A1/es active IP Right Grant
- 2014-01-29 RS RS20170516A patent/RS56015B1/sr unknown
- 2014-01-29 GE GEAP201414909A patent/GEP20207177B/en unknown
- 2014-01-29 BR BR112015018289A patent/BR112015018289A2/pt not_active Application Discontinuation
- 2014-01-29 MX MX2015009602A patent/MX2015009602A/es unknown
- 2014-01-29 ES ES17152492T patent/ES2857687T3/es active Active
- 2014-01-29 KR KR1020157023601A patent/KR102227592B1/ko active IP Right Grant
- 2014-01-29 RU RU2015136795A patent/RU2662223C2/ru active
- 2014-01-29 HU HUE14704053A patent/HUE033370T2/en unknown
- 2014-01-29 PT PT147040539T patent/PT2953931T/pt unknown
- 2014-01-29 AP AP2015008633A patent/AP2015008633A0/xx unknown
- 2014-01-29 EP EP14704053.9A patent/EP2953931B1/en active Active
- 2014-01-29 EP EP20216557.7A patent/EP3865475A1/en active Pending
- 2014-01-29 AU AU2014212509A patent/AU2014212509B2/en active Active
- 2014-01-29 UA UAA201508443A patent/UA120589C2/uk unknown
- 2014-01-29 NZ NZ750187A patent/NZ750187A/en unknown
- 2014-01-29 SI SI201430220T patent/SI2953931T1/sl unknown
- 2014-01-29 TW TW108105717A patent/TWI714967B/zh active
- 2014-01-29 US US14/167,759 patent/US9051270B2/en active Active
- 2014-01-29 SG SG11201505953TA patent/SG11201505953TA/en unknown
- 2014-01-29 UY UY0001035288A patent/UY35288A/es active IP Right Grant
-
2015
- 2015-04-29 US US14/699,437 patent/US9393235B2/en active Active
- 2015-07-27 PH PH12015501661A patent/PH12015501661A1/en unknown
- 2015-07-28 IL IL24019515A patent/IL240195B/en active IP Right Grant
- 2015-07-31 CL CL2015002147A patent/CL2015002147A1/es unknown
-
2016
- 2016-05-13 HK HK16105503.1A patent/HK1217693A1/zh unknown
- 2016-06-06 US US15/174,896 patent/US9758483B2/en active Active
-
2017
- 2017-05-26 HR HRP20170787TT patent/HRP20170787T1/hr unknown
- 2017-05-31 CY CY20171100560T patent/CY1119163T1/el unknown
- 2017-08-03 US US15/667,722 patent/US10087143B2/en active Active
-
2018
- 2018-02-20 JP JP2018027902A patent/JP6741704B2/ja active Active
- 2018-03-15 HK HK18103628.4A patent/HK1244269A1/zh unknown
- 2018-08-09 AU AU2018214105A patent/AU2018214105B9/en active Active
- 2018-08-21 US US16/107,109 patent/US10738009B2/en active Active
-
2019
- 2019-03-25 JP JP2019056505A patent/JP2019089861A/ja not_active Withdrawn
-
2020
- 2020-06-24 US US16/910,965 patent/US11673864B2/en active Active
- 2020-07-02 AU AU2020204425A patent/AU2020204425A1/en not_active Abandoned
- 2020-10-07 JP JP2020169731A patent/JP2021001232A/ja active Pending
-
2021
- 2021-03-01 HR HRP20210349TT patent/HRP20210349T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20210349T1 (hr) | Piridon amidi kao modulatori natrijevih kanala | |
JP2016506963A5 (hr) | ||
RU2016105511A (ru) | Сульфонамиды в качестве молдуляторов натриевых каналов | |
JP2016525122A5 (hr) | ||
JP2016508500A5 (hr) | ||
RU2015136779A (ru) | Амиды в качестве модуляторов натриевых каналов | |
CA2601508A1 (en) | Cyclopropanecarboxamide derivatives | |
HRP20191821T1 (hr) | Antiproliferativni spojevi i načini njihove uporabe | |
RU2015136770A (ru) | Хинолинамиды и хиназолинамиды в качестве модуляторов натриевых каналов | |
HRP20201430T1 (hr) | Spojevi 6-heterociklil-4-morfolin-4-ilpiridin-2-ona korisni za liječenje karcinoma i dijabetesa | |
JP2018534282A5 (hr) | ||
RU2015108894A (ru) | СОЕДИНЕНИЯ 4-ГЕТЕРОАРИЛЗАМЕЩЕННОЙ БЕНЗОЙНОЙ КИСЛОТЫ В КАЧЕСТВЕ ИНГИБИТОРОВ RORгаммаТ И ИХ ПРИМЕНЕНИЯ | |
JP2010530438A5 (hr) | ||
RU2017145650A (ru) | Ингибиторы тирозинкиназы брутона | |
RU2017116197A (ru) | 2-амино-3,5-дифтор-3,6-диметил-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 для лечения болезни альцгеймера | |
RU2016137674A (ru) | Производные пиперидиндиона | |
JP2016534134A5 (hr) | ||
RU2015113746A (ru) | Замещенные сульфонамиды | |
JP2008510714A5 (hr) | ||
RU2009116670A (ru) | Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина | |
RU2015144385A (ru) | Ациклические цианоэтилпиразолопиридоны в качестве ингибиторов янус-киназы | |
RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
RU2012116877A (ru) | Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы | |
RU2017120217A (ru) | 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1 | |
JP2016523935A5 (hr) |